|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HUP0104865A3
(en)
*
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
CA2398466A1
(en)
*
|
2000-01-27 |
2001-08-02 |
Medimmune, Inc. |
Ultra high affinity neutralizing antibodies
|
|
JP2003525061A
(ja)
|
2000-03-01 |
2003-08-26 |
メディミューン,インコーポレイテッド |
高効力組換え抗体およびその産生法
|
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US7179900B2
(en)
*
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US7658921B2
(en)
*
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
|
EP1355919B1
(en)
*
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
US20040002587A1
(en)
*
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US7317091B2
(en)
*
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040132101A1
(en)
*
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
US20050152899A1
(en)
*
|
2002-05-10 |
2005-07-14 |
Kinch Michael S. |
EphA2 agonistic monoclonal antibodies and methods of use thereof
|
|
EP1575509B1
(en)
*
|
2002-05-10 |
2011-10-26 |
Purdue Research Foundation |
Epha2 agonistic monoclonal antibodies and methods of use thereof
|
|
EP1519956B1
(en)
*
|
2002-05-10 |
2011-09-21 |
Medimmune, Inc. |
Epha2 monoclonal antibodies and methods of use thereof
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
US7132100B2
(en)
*
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US7217797B2
(en)
*
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US7365168B2
(en)
*
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
ATE480562T1
(de)
*
|
2002-10-15 |
2010-09-15 |
Facet Biotech Corp |
Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
AU2004204817C1
(en)
|
2003-01-13 |
2011-01-20 |
Macrogenics, Inc. |
Soluble FcyR fusion proteins and methods of use thereof
|
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
CN1798767B
(zh)
*
|
2003-04-10 |
2011-02-16 |
晶面生物技术公司 |
通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期
|
|
EP1617864A4
(en)
*
|
2003-04-11 |
2006-06-21 |
Medimmune Inc |
EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING
|
|
KR101224235B1
(ko)
|
2003-04-11 |
2013-01-25 |
메디뮨 엘엘씨 |
재조합 il9 항체 및 그의 용도
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
DK1639014T3
(da)
*
|
2003-06-13 |
2011-01-17 |
Biogen Idec Inc |
Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
|
|
JP4178514B2
(ja)
*
|
2003-06-27 |
2008-11-12 |
東洋紡績株式会社 |
抗体のスクリーニング方法
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
AU2004266159A1
(en)
*
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
DK2520654T3
(en)
*
|
2003-08-26 |
2017-05-01 |
Univ Colorado Regents |
Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
EP1673395A1
(en)
|
2003-10-15 |
2006-06-28 |
PDL BioPharma, Inc. |
Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
|
|
WO2005063815A2
(en)
*
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
|
EP1697520A2
(en)
*
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
AU2005249360B2
(en)
|
2004-04-12 |
2011-07-21 |
Medimmune, Llc |
Anti-IL-9 antibody formulations and uses thereof
|
|
NZ551180A
(en)
|
2004-06-01 |
2009-10-30 |
Genentech Inc |
Antibody drug conjugates and methods
|
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
|
AU2005287406B2
(en)
*
|
2004-07-26 |
2011-08-18 |
Biogen Ma Inc. |
Anti-CD154 antibodies
|
|
BRPI0514068B8
(pt)
|
2004-08-04 |
2021-05-25 |
Applied Molecular Evolution Inc |
anticorpo anti-cd20, e, composição farmacêutica
|
|
AU2005277641A1
(en)
*
|
2004-08-16 |
2006-03-02 |
Medimmune, Llc |
Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
|
|
CA2577133A1
(en)
*
|
2004-08-19 |
2006-03-23 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
CA2585891A1
(en)
*
|
2004-10-29 |
2006-05-11 |
Medimmune, Inc. |
Methods of preventing and treating rsv infections and related conditions
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US9200079B2
(en)
|
2004-11-12 |
2015-12-01 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US7450994B1
(en)
|
2004-12-16 |
2008-11-11 |
Advanced Bionics, Llc |
Estimating flap thickness for cochlear implants
|
|
ATE423140T1
(de)
|
2005-01-05 |
2009-03-15 |
F Star Biotech Forsch & Entw |
Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
|
|
CA2595169A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
|
CA2591914C
(en)
*
|
2005-01-24 |
2017-04-25 |
Board Of Regents, The University Of Texas System |
Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
|
|
PT1853718E
(pt)
|
2005-02-15 |
2015-11-12 |
Univ Duke |
Anticorpos anti-cd19 e usos em oncologia
|
|
US20060263357A1
(en)
|
2005-05-05 |
2006-11-23 |
Tedder Thomas F |
Anti-CD19 antibody therapy for autoimmune disease
|
|
US8999943B2
(en)
|
2005-03-14 |
2015-04-07 |
Board Of Regents, The University Of Texas System |
Antigene oligomers inhibit transcription
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
JP5838021B2
(ja)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディとその使用
|
|
CA2606102C
(en)
*
|
2005-04-26 |
2014-09-30 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
|
CN101198624B
(zh)
|
2005-05-06 |
2012-10-10 |
津莫吉尼蒂克斯公司 |
Il-31单克隆抗体及使用方法
|
|
WO2006130834A2
(en)
|
2005-05-31 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
|
|
WO2007094842A2
(en)
|
2005-12-02 |
2007-08-23 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
|
WO2007005612A2
(en)
*
|
2005-07-01 |
2007-01-11 |
Medimmune, Inc. |
An integrated approach for generating multidomain protein therapeutics
|
|
WO2007008943A2
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
|
DK2573114T3
(en)
|
2005-08-10 |
2016-07-04 |
Macrogenics Inc |
The identification and production of antibodies with variant Fc regions, and methods of using same
|
|
DK1931709T3
(en)
*
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
|
JP4860703B2
(ja)
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗cd30抗体
|
|
AU2006304387A1
(en)
|
2005-10-14 |
2007-04-26 |
Medimmune, Llc |
Cell display of antibody libraries
|
|
EP1957531B1
(en)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
|
CA2629664A1
(en)
|
2005-11-17 |
2007-08-02 |
Board Of Regents, The University Of Texas System |
Modulation of gene expression by oligomers targeted to chromosomal dna
|
|
US20070122413A1
(en)
|
2005-11-28 |
2007-05-31 |
Sivakumar Pallavur V |
Il-21 antagonists
|
|
KR101866623B1
(ko)
*
|
2005-11-28 |
2018-07-04 |
젠맵 에이/에스 |
재조합 1가 항체 및 그의 제조 방법
|
|
JP2009525986A
(ja)
*
|
2006-02-03 |
2009-07-16 |
メディミューン,エルエルシー |
タンパク質製剤
|
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
JP5144499B2
(ja)
*
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
二重特異性抗体を精製するための抗体改変方法
|
|
EP4793360A2
(en)
*
|
2006-03-31 |
2026-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
PT2032606E
(pt)
|
2006-05-30 |
2014-02-05 |
Genentech Inc |
Anticorpos e imunoconjugados e respetivas utilizações
|
|
EP2032159B1
(en)
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
|
EP2029173B1
(en)
|
2006-06-26 |
2016-07-20 |
MacroGenics, Inc. |
Fc riib-specific antibodies and methods of use thereof
|
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
|
WO2008112004A2
(en)
|
2006-08-03 |
2008-09-18 |
Astrazeneca Ab |
ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
|
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
|
KR20090058512A
(ko)
|
2006-08-04 |
2009-06-09 |
아스트라제네카 아베 |
Erbb2에 대한 인간 항체
|
|
RS53263B
(sr)
|
2006-08-14 |
2014-08-29 |
Xencor Inc. |
Optimizovana antitela usmerena na cd19
|
|
EP2061811A2
(en)
|
2006-09-01 |
2009-05-27 |
ZymoGenetics, Inc. |
Variable region sequences of il-31 monoclonal antibodies and methods of use
|
|
US8323653B2
(en)
|
2006-09-08 |
2012-12-04 |
Medimmune, Llc |
Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
EP2064240A2
(en)
|
2006-09-18 |
2009-06-03 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
|
EP2064335A4
(en)
*
|
2006-10-16 |
2011-03-30 |
Medimmune Llc |
MOLECULES WITH REDUCED HALF TIME, COMPOSITIONS AND ITS USE
|
|
PT2845866T
(pt)
|
2006-10-27 |
2017-08-09 |
Genentech Inc |
Anticorpos e imunoconjugados e utilizações dos mesmos
|
|
CN101678100A
(zh)
|
2006-12-06 |
2010-03-24 |
米迪缪尼有限公司 |
治疗系统性红斑狼疮的方法
|
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
US20080248033A1
(en)
|
2006-12-19 |
2008-10-09 |
Genentech, Inc. |
VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
|
|
EP3199180B1
(en)
|
2007-03-08 |
2022-01-05 |
Humanigen, Inc. |
Epha3 antibodies for the treatment of solid tumors
|
|
EP1980269A1
(en)
*
|
2007-04-13 |
2008-10-15 |
Katholieke Universiteit Leuven |
Prevention of staphylococcus biofilm formation
|
|
BRPI0811466A2
(pt)
|
2007-05-07 |
2014-10-14 |
Medimmune Llc |
Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
|
|
CA2693053C
(en)
|
2007-05-30 |
2021-01-05 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
|
PL3241842T3
(pl)
|
2007-06-26 |
2024-06-10 |
F-Star Therapeutics Limited |
Prezentacja środków wiążących
|
|
US20110077383A1
(en)
*
|
2007-07-03 |
2011-03-31 |
Medimmune, Llc |
Hinge domain engineering
|
|
CN101952312A
(zh)
|
2007-07-31 |
2011-01-19 |
米迪缪尼有限公司 |
多特异性表位结合蛋白及其应用
|
|
PE20090499A1
(es)
|
2007-08-09 |
2009-05-18 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
|
MX2010000232A
(es)
*
|
2007-08-21 |
2010-06-02 |
Morphosys Ag |
Metodos mejorados para la formacion de enlaces disulfuro.
|
|
ES2687808T3
(es)
|
2007-09-26 |
2018-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
|
AU2008324800B2
(en)
|
2007-11-05 |
2014-03-27 |
Astrazeneca Ab |
Methods of treating scleroderma
|
|
WO2009060198A1
(en)
|
2007-11-09 |
2009-05-14 |
Peregrine Pharmaceuticals, Inc. |
Anti-vegf antibody compositions and methods
|
|
EP2217268B1
(en)
|
2007-12-07 |
2016-05-04 |
ZymoGenetics, Inc. |
Anti-human il-21 monoclonal antibodies
|
|
SI2796466T1
(en)
|
2007-12-07 |
2018-01-31 |
Zymogenetics, Inc. |
Molecules of Humanized Specifics Specifiable for IL-31
|
|
WO2009117030A2
(en)
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
|
MX2010006735A
(es)
|
2007-12-21 |
2010-09-30 |
Medimmune Ltd |
Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
|
|
US8092804B2
(en)
*
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
KR101616758B1
(ko)
|
2007-12-26 |
2016-04-29 |
젠코어 인코포레이티드 |
FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
|
|
KR20100107501A
(ko)
|
2008-01-18 |
2010-10-05 |
메디뮨 엘엘씨 |
부위 특이적 접합을 위한 시스테인 조작 항체
|
|
EP2080770A1
(en)
*
|
2008-01-21 |
2009-07-22 |
MorphoSys AG |
Proteinaceous binding molecules comprising purification tags
|
|
MX2010008578A
(es)
|
2008-02-08 |
2010-11-10 |
Medimmune Llc |
Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
SG189730A1
(en)
|
2008-04-02 |
2013-05-31 |
Macrogenics Inc |
Her2/neu-specific antibodies and methods of using same
|
|
CN106349390B
(zh)
|
2008-04-02 |
2019-12-10 |
宏观基因有限公司 |
Bcr-复合体-特异性抗体和其使用方法
|
|
TW201920257A
(zh)
|
2008-04-11 |
2019-06-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗原結合分子
|
|
WO2009129538A2
(en)
*
|
2008-04-18 |
2009-10-22 |
Xencor, Inc. |
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
AR077718A1
(es)
*
|
2008-07-15 |
2011-09-21 |
Genentech Inc |
Metodos para tratar enfermedades autoinmunes usando anticuerpos anti cd4. formulacion farmaceutica
|
|
CN102264763B
(zh)
|
2008-09-19 |
2016-04-27 |
米迪缪尼有限公司 |
定向于dll4的抗体及其用途
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
AU2009303526B2
(en)
*
|
2008-10-14 |
2015-01-15 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
|
WO2010056804A1
(en)
|
2008-11-12 |
2010-05-20 |
Medimmune, Llc |
Antibody formulation
|
|
KR20180117734A
(ko)
|
2008-11-22 |
2018-10-29 |
제넨테크, 인크. |
유방암의 치료를 위한, 화학요법과 조합된 항-vegf 항체의 용도
|
|
US8775090B2
(en)
|
2008-12-12 |
2014-07-08 |
Medimmune, Llc |
Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
|
|
EP2379595A2
(en)
|
2008-12-23 |
2011-10-26 |
AstraZeneca AB |
Targeted binding agents directed to 5 1 and uses thereof
|
|
CN102341411A
(zh)
|
2008-12-31 |
2012-02-01 |
比奥根艾迪克Ma公司 |
抗-淋巴细胞毒素抗体
|
|
CN102387814A
(zh)
*
|
2009-01-29 |
2012-03-21 |
米迪缪尼有限公司 |
延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
|
|
US8834870B2
(en)
|
2009-03-06 |
2014-09-16 |
Kalobios Pharmaceuticals, Inc. |
Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
|
|
MX355507B
(es)
|
2009-03-09 |
2018-04-19 |
Bioatla Llc |
Proteinas mirac.
|
|
MX2011009704A
(es)
*
|
2009-03-16 |
2011-09-28 |
Cephalon Australia Pty Ltd |
Anticuerpos humanizados con actividad anti-tumor.
|
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
TWI544077B
(zh)
|
2009-03-19 |
2016-08-01 |
中外製藥股份有限公司 |
Antibody constant region change body
|
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
|
ES2549769T3
(es)
|
2009-03-25 |
2015-11-02 |
Genentech, Inc. |
Anticuerpos anti-FGFR3 y métodos que emplean los mismos
|
|
NZ616382A
(en)
|
2009-04-20 |
2015-04-24 |
Oxford Biotherapeutics Ltd |
Antibodies specific to cadherin-17
|
|
EP2437767B1
(en)
*
|
2009-06-01 |
2015-07-08 |
MedImmune, LLC |
Molecules with extended half-lives and uses thereof
|
|
BRPI1015234A2
(en)
|
2009-06-22 |
2018-02-20 |
Medimmune Llc |
fc regions designed for site specific conjugation.
|
|
EP2464661B1
(en)
|
2009-08-13 |
2018-01-17 |
The Johns Hopkins University |
Methods of modulating immune function with anti-b7-h7cr antibodies
|
|
MX2012001882A
(es)
|
2009-08-13 |
2012-04-11 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
|
KR20120107069A
(ko)
|
2009-08-15 |
2012-09-28 |
제넨테크, 인크. |
이전에 치료된 유방암의 치료를 위한 항혈관신생 요법
|
|
CA2771999A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
AU2010292172A1
(en)
|
2009-09-09 |
2012-05-03 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
|
US10150808B2
(en)
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
|
MX2012004029A
(es)
|
2009-10-07 |
2012-05-08 |
Macrogenics Inc |
Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
|
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
|
AU2010313621C1
(en)
|
2009-10-14 |
2015-11-26 |
Humanigen, Inc. |
Antibodies to EphA3
|
|
EP2491059B1
(en)
|
2009-10-22 |
2015-02-25 |
F.Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods using same
|
|
HUE041426T2
(hu)
|
2009-11-02 |
2019-05-28 |
Univ Washington |
Terápiás nukleáz-készítmények és eljárások
|
|
CA2780221A1
(en)
|
2009-11-04 |
2011-05-12 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
|
KR101968766B1
(ko)
|
2009-11-05 |
2019-04-12 |
제넨테크, 인크. |
이종 폴리펩티드의 분비를 위한 방법 및 조성물
|
|
CA2778552A1
(en)
|
2009-11-05 |
2011-05-12 |
Cephalon Australia Pty Ltd |
Treatment of cancer involving mutated kras or braf genes
|
|
US8881354B2
(en)
|
2009-11-16 |
2014-11-11 |
Jtekt Corporation |
Tool radius adjusting system for boring holder, tool radius adjusting method in machine tool, and machine tool
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
ES2573642T3
(es)
|
2009-12-23 |
2016-06-09 |
Synimmune Gmbh |
Anticuerpos anti-FLT3 y métodos de usar los mismos
|
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
|
MX2012008085A
(es)
|
2010-01-13 |
2012-09-12 |
Oncomed Pharm Inc |
Agentes de union notch1 y metodos de uso de los mismos.
|
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
|
AR080154A1
(es)
|
2010-02-10 |
2012-03-14 |
Immunogen Inc |
Anticuerpos cd20 y su utilizacion
|
|
WO2011102845A1
(en)
*
|
2010-02-18 |
2011-08-25 |
Transtech Pharma, Inc. |
Rage fusion protein compositions and methods of use
|
|
SG10201401123VA
(en)
|
2010-02-23 |
2014-08-28 |
Genentech Inc |
Anti-Angiogenesis Therapy For The Treatment Of Ovarian Cancer
|
|
CN103805202B
(zh)
|
2010-02-25 |
2018-05-18 |
旭化成株式会社 |
氧化铜用蚀刻液以及使用其的蚀刻方法
|
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
DK2542256T3
(da)
|
2010-03-04 |
2019-08-26 |
Macrogenics Inc |
Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
|
|
WO2011113019A2
(en)
|
2010-03-12 |
2011-09-15 |
Abbott Biotherapeutics Corp. |
Ctla4 proteins and their uses
|
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
|
AU2011245117B2
(en)
|
2010-04-30 |
2015-03-12 |
Alexion Pharmaceuticals, Inc. |
Anti-C5a antibodies and methods for using the antibodies
|
|
AU2011258425B2
(en)
|
2010-05-27 |
2015-12-10 |
Merck Sharp & Dohme Llc |
Method for preparing antibodies having improved properties
|
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
|
NZ701208A
(en)
|
2010-06-03 |
2016-05-27 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
|
|
MX380504B
(es)
|
2010-06-03 |
2025-03-12 |
Pharmacyclics Llc |
El uso de inhibidores de la tirosina quinasa de bruton (btk).
|
|
BR112012033119A2
(pt)
|
2010-06-22 |
2016-10-25 |
Univ Colorado Regents |
anticorpos para o fragamento c3d do componente do complemento 3.
|
|
EP2591000B1
(en)
|
2010-07-09 |
2017-05-17 |
Janssen Vaccines & Prevention B.V. |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
|
PT2591006T
(pt)
|
2010-07-09 |
2019-07-29 |
Bioverativ Therapeutics Inc |
Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
|
|
JP5972871B2
(ja)
|
2010-07-20 |
2016-08-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗il−23ヘテロ二量体特異的抗体
|
|
SG187592A1
(en)
|
2010-07-23 |
2013-03-28 |
Univ Boston |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
|
HRP20230776T1
(hr)
|
2010-07-29 |
2023-10-27 |
Buzzard Pharmaceuticals AB |
Himerni antagonisti receptora il-1 tipa i
|
|
ES2667100T3
(es)
|
2010-08-02 |
2018-05-09 |
Macrogenics, Inc. |
Diacuerpos covalentes y sus usos
|
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
|
JP2013537416A
(ja)
|
2010-08-13 |
2013-10-03 |
メディミューン リミテッド |
変異型Fc領域を含むモノマーポリペプチド及び使用方法
|
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
|
SG10201506782XA
(en)
|
2010-08-27 |
2015-10-29 |
Stem Centrx Inc |
Notum protein modulators and methods of use
|
|
CN106620693A
(zh)
|
2010-09-03 |
2017-05-10 |
艾伯维施特姆森特克斯有限责任公司 |
新型调节剂及使用方法
|
|
US9228023B2
(en)
|
2010-10-01 |
2016-01-05 |
Oxford Biotherapeutics Ltd. |
Anti-ROR1 antibodies and methods of use for treatment of cancer
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
PH12013500703A1
(en)
|
2010-10-13 |
2013-05-20 |
Janssen Biotech Inc |
Human oncostatin m antibodies and methods of use
|
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
|
CN105859889B
(zh)
|
2010-11-17 |
2020-01-07 |
中外制药株式会社 |
具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
|
|
MX351887B
(es)
|
2010-11-23 |
2017-11-01 |
Glaxo Group Ltd |
Proteinas de union a antigeno para oncostatina m (osm).
|
|
MX2013005847A
(es)
|
2010-11-24 |
2013-12-12 |
Glaxo Group Ltd |
Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
|
|
TWI654203B
(zh)
|
2010-11-30 |
2019-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
具有鈣依存性的抗原結合能力之抗體
|
|
TWI736437B
(zh)
|
2010-11-30 |
2021-08-11 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
|
PH12013501137A1
(en)
|
2010-12-08 |
2021-06-02 |
Abbvie Stemcentrx Llc |
Novel modulators and methods of use
|
|
AU2011349049B2
(en)
*
|
2010-12-22 |
2016-08-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Modified antibody with improved half-life
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
WO2012103240A2
(en)
|
2011-01-25 |
2012-08-02 |
Eleven Biotherapeutics, Inc. |
Receptor binding agents
|
|
TW201244737A
(en)
|
2011-02-03 |
2012-11-16 |
Alexion Pharma Inc |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
RS58190B2
(sr)
|
2011-02-08 |
2021-08-31 |
Medimmune Llc |
Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene
|
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
|
SG10201609665PA
(en)
|
2011-02-25 |
2017-01-27 |
Chugai Pharmaceutical Co Ltd |
FcɣRIIb-SPECIFIC Fc ANTIBODY
|
|
LT2691417T
(lt)
|
2011-03-29 |
2018-10-25 |
Roche Glycart Ag |
Antikūno fc variantai
|
|
RU2013150331A
(ru)
|
2011-04-20 |
2015-05-27 |
Рош Гликарт Аг |
СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
|
|
EP2699256B1
(en)
|
2011-04-21 |
2017-09-27 |
The Regents of the University of Colorado, a body corporate |
Compositions and methods for the treatment of neuromyelitis optica
|
|
CA2834626A1
(en)
|
2011-04-29 |
2012-11-01 |
University Of Washington |
Therapeutic nuclease compositions and methods
|
|
US9376495B2
(en)
|
2011-05-21 |
2016-06-28 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use in extending serum half-life
|
|
DK2714738T3
(en)
|
2011-05-24 |
2019-01-28 |
Zyngenia Inc |
MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
|
|
AU2012258907A1
(en)
|
2011-05-25 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
Method for preparing Fc-containing polypeptides having improved properties
|
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
|
AU2012267732A1
(en)
|
2011-06-10 |
2014-01-09 |
Medimmune Limited |
Anti-Pseudomonas Psl binding molecules and uses thereof
|
|
CA2838833A1
(en)
|
2011-06-10 |
2012-12-13 |
Biogen Idec Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
|
RU2605595C2
(ru)
|
2011-06-13 |
2016-12-20 |
СиЭсЭл Лимитид |
Антитела против g-csfr и их применение
|
|
EP3628327A1
(en)
|
2011-06-24 |
2020-04-01 |
The Regents of the University of Colorado, A Body Corporate |
Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
|
|
SMT201900520T1
(it)
*
|
2011-06-28 |
2019-11-13 |
Inhibrx Lp |
Polipeptidi di fusione serpinici e relativi metodi d'uso
|
|
RU2639526C2
(ru)
*
|
2011-06-28 |
2017-12-21 |
ИНХИБРКС ЭлЭлСи |
Слитые полипептиды, содержащие домен wap, и способы их применения
|
|
US10400029B2
(en)
*
|
2011-06-28 |
2019-09-03 |
Inhibrx, Lp |
Serpin fusion polypeptides and methods of use thereof
|
|
EA031181B1
(ru)
|
2011-06-28 |
2018-11-30 |
Оксфорд Байотерепьютикс Лтд. |
Антитело, которое специфически связывается с bst1, или его антигенсвязывающий фрагмент, нуклеиновые кислоты, кодирующие его цепи, клетка-хозяин, способ получения этого антитела и применение для лечения рака и воспалительных заболеваний
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
|
WO2013012747A1
(en)
|
2011-07-15 |
2013-01-24 |
Oncomed Pharmaceuticals, Inc. |
Rspo binding agents and uses thereof
|
|
GB201112429D0
(en)
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
|
EP2548892A1
(en)
|
2011-07-22 |
2013-01-23 |
CSL Behring GmbH |
Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
|
|
HRP20250164T1
(hr)
|
2011-07-22 |
2025-04-11 |
Csl Behring Gmbh |
Inhibitorna monoklonska antitijela protiv faktora xii/xiia i njihove uporabe
|
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
|
PH12014500220A1
(en)
|
2011-07-27 |
2019-03-22 |
Glaxo Group Ltd |
Anti-vegf single variable domains fused to fc domains
|
|
SG10201606218WA
(en)
|
2011-07-29 |
2016-09-29 |
Eleven Biotherapeutics Inc |
Purified Proteins
|
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
|
TWI583699B
(zh)
|
2011-09-23 |
2017-05-21 |
安可美德藥物股份有限公司 |
Vegf/dll4結合劑類及彼等之用途
|
|
EP3495389A1
(en)
|
2011-09-30 |
2019-06-12 |
Teva Pharmaceuticals Australia Pty Ltd |
Antibodies against tl1a and uses thereof
|
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
|
KR102366029B1
(ko)
|
2011-09-30 |
2022-02-23 |
추가이 세이야쿠 가부시키가이샤 |
표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
KR20250078601A
(ko)
|
2011-09-30 |
2025-06-02 |
추가이 세이야쿠 가부시키가이샤 |
항원의 소실을 촉진시키는 항원 결합 분자
|
|
EP2765192A4
(en)
|
2011-10-05 |
2015-04-15 |
Chugai Pharmaceutical Co Ltd |
ANTIGENBINDING MOLECULE FOR PREPARING A SPACE BETWEEN A PLASMA AND AN ANTIGEN WITH A SACCHARIDE CHAIN RECEPTOR BINDING DOMAIN
|
|
KR102434073B1
(ko)
|
2011-10-11 |
2022-08-18 |
비엘라 바이오, 인크. |
Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
|
|
BR112014009866A2
(pt)
|
2011-10-25 |
2018-09-04 |
Onclave Therapeutics Limited |
formulações de anticorpos e métodos
|
|
CN104203982B
(zh)
|
2011-10-28 |
2018-08-31 |
特瓦制药澳大利亚私人有限公司 |
多肽构建体及其用途
|
|
WO2013067060A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
|
ES2697674T3
(es)
|
2011-11-01 |
2019-01-25 |
Bionomics Inc |
Procedimientos para bloquear el crecimiento de células madre cancerosas
|
|
HK1201855A1
(en)
|
2011-11-01 |
2015-09-11 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
|
EP2773664A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
|
US9574010B2
(en)
|
2011-11-04 |
2017-02-21 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
WO2013070615A1
(en)
|
2011-11-07 |
2013-05-16 |
Medlmmune, Llc. |
Combination therapies using anti- pseudomonas psl and pcrv binding molecules
|
|
CN103906533A
(zh)
|
2011-11-07 |
2014-07-02 |
米迪缪尼有限公司 |
多特异性和多价结合蛋白及其用途
|
|
EP2780463A4
(en)
*
|
2011-11-18 |
2015-07-01 |
Merck Sharp & Dohme |
FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
|
|
CN108424456B
(zh)
|
2011-11-23 |
2022-04-26 |
医学免疫有限责任公司 |
特异于her3的结合分子及其用途
|
|
KR20210074395A
(ko)
|
2011-11-30 |
2021-06-21 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약
|
|
CN107353342B
(zh)
|
2011-12-05 |
2021-08-10 |
X 博迪生物科学公司 |
PDGF受体β结合多肽
|
|
US9527927B2
(en)
|
2011-12-20 |
2016-12-27 |
Medimmune, Llc |
Modified polypeptides for bispecific antibody scaffolds
|
|
WO2013096221A1
(en)
*
|
2011-12-21 |
2013-06-27 |
Amgen Inc. |
Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
|
|
WO2013096948A1
(en)
|
2011-12-23 |
2013-06-27 |
Lydon Nicholas B |
Immunoglobulins and variants directed against pathogenic microbes
|
|
EP3539982B1
(en)
|
2011-12-23 |
2025-02-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
US9988439B2
(en)
|
2011-12-23 |
2018-06-05 |
Nicholas B. Lydon |
Immunoglobulins and variants directed against pathogenic microbes
|
|
KR102041412B1
(ko)
*
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Fc 단편 유도체
|
|
KR20140137347A
(ko)
|
2012-01-10 |
2014-12-02 |
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 |
알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
|
|
HRP20191920T1
(hr)
|
2012-01-12 |
2020-01-10 |
Bioverativ Therapeutics Inc. |
Kimerni polipeptidi faktora viii i njihova uporaba
|
|
EP2623110A1
(en)
|
2012-01-31 |
2013-08-07 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of neurological inflammatory disorders
|
|
EP4624490A3
(en)
*
|
2012-02-09 |
2025-11-05 |
Chugai Seiyaku Kabushiki Kaisha |
Modified fc region of antibody
|
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
|
WO2013123457A1
(en)
|
2012-02-15 |
2013-08-22 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
|
CN104520324A
(zh)
|
2012-02-24 |
2015-04-15 |
施特姆森特Rx股份有限公司 |
Dll3调节剂及其使用方法
|
|
CA2865158C
(en)
|
2012-02-24 |
2022-11-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
|
|
WO2013148296A1
(en)
|
2012-03-28 |
2013-10-03 |
Sanofi |
Antibodies to bradykinin b1 receptor ligands
|
|
US10385395B2
(en)
|
2012-04-11 |
2019-08-20 |
The Regents Of The University Of California |
Diagnostic tools for response to 6-thiopurine therapy
|
|
US9212227B2
(en)
|
2012-04-30 |
2015-12-15 |
Janssen Biotech, Inc. |
ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
|
|
CA2871934C
(en)
*
|
2012-04-30 |
2023-06-13 |
Medimmune, Llc |
Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
|
|
WO2013169657A1
(en)
|
2012-05-07 |
2013-11-14 |
Sanofi |
Methods for preventing biofilm formation
|
|
JP6351572B2
(ja)
|
2012-05-10 |
2018-07-04 |
ザイムワークス,インコーポレイテッド |
Fcドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
|
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
|
JPWO2013180201A1
(ja)
|
2012-05-30 |
2016-01-21 |
中外製薬株式会社 |
会合化した抗原を消失させる抗原結合分子
|
|
WO2013180200A1
(ja)
|
2012-05-30 |
2013-12-05 |
中外製薬株式会社 |
標的組織特異的抗原結合分子
|
|
MX2014014951A
(es)
|
2012-06-06 |
2015-03-13 |
Oncomed Pharm Inc |
Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
|
|
AU2013270683A1
(en)
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Chimeric clotting factors
|
|
AU2013270682A1
(en)
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Procoagulant compounds
|
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
WO2014006217A1
(en)
|
2012-07-06 |
2014-01-09 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
US10023628B2
(en)
|
2012-07-06 |
2018-07-17 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor VIII polypeptides and uses thereof
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
ES2770501T3
(es)
|
2012-07-11 |
2020-07-01 |
Bioverativ Therapeutics Inc |
Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
|
|
SI3495387T1
(sl)
|
2012-07-13 |
2021-12-31 |
Roche Glycart Ag |
Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
|
|
HK1206073A1
(en)
|
2012-07-24 |
2015-12-31 |
药品循环有限责任公司 |
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
|
|
EP4063391A1
(en)
|
2012-07-25 |
2022-09-28 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
|
EP2888279A1
(en)
|
2012-08-22 |
2015-07-01 |
Glaxo Group Limited |
Anti lrp6 antibodies
|
|
TWI855488B
(zh)
|
2012-08-24 |
2024-09-11 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
JP6774164B2
(ja)
|
2012-08-24 |
2020-10-21 |
中外製薬株式会社 |
マウスFcγRII特異的Fc抗体
|
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
|
FI3366705T3
(fi)
|
2012-09-12 |
2023-07-28 |
Genzyme Corp |
Muuttuneen glykosylaation ja vähentyneen efektoritoiminnan omaavia fc:n sisältäviä polypeptidejä
|
|
WO2014066744A2
(en)
|
2012-10-25 |
2014-05-01 |
True North Therapeutics, Inc. |
Anti-complement c1s antibodies and uses thereof
|
|
ES2912396T3
(es)
|
2012-11-02 |
2022-05-25 |
Bioverativ Usa Inc |
Anticuerpos anti-C1s del complemento y uso de los mismos
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
WO2014089169A2
(en)
|
2012-12-04 |
2014-06-12 |
Oncomed Pharmaceuticals, Inc. |
Immunotherapy with binding agents
|
|
AU2013361275B2
(en)
|
2012-12-19 |
2016-11-24 |
Amplimmune, Inc. |
Anti-human B7-H4 antibodies and their uses
|
|
JP6359031B2
(ja)
|
2012-12-21 |
2018-07-18 |
メディミューン,エルエルシー |
抗h7cr抗体
|
|
MX387324B
(es)
|
2013-01-10 |
2025-03-18 |
Genmab Bv |
Variantes de regiones fc de igg1 de humano y usos de las mismas.
|
|
WO2014114651A1
(en)
|
2013-01-24 |
2014-07-31 |
Glaxosmithkline Intellectual Property Development Limited |
Tnf-alpha antigen-binding proteins
|
|
CA2898121A1
(en)
|
2013-01-25 |
2014-07-31 |
Shire Human Genetic Therapies, Inc. |
Follistatin in treating duchenne muscular dystrophy
|
|
AU2014213009B2
(en)
|
2013-02-01 |
2019-01-03 |
Kira Biotech Pty Limited |
Anti-CD83 antibodies and use thereof
|
|
CN105073195A
(zh)
|
2013-02-04 |
2015-11-18 |
昂科梅德制药有限公司 |
使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
|
|
PT2953971T
(pt)
|
2013-02-07 |
2023-05-02 |
Csl Ltd |
Proteínas de ligação à il-11r e suas utilizações
|
|
RS61387B2
(sr)
|
2013-02-15 |
2024-06-28 |
Bioverativ Therapeutics Inc |
Gen optimizovanog faktora viii
|
|
ES2731681T3
(es)
|
2013-02-22 |
2019-11-18 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
WO2014135694A1
(en)
|
2013-03-08 |
2014-09-12 |
Csl Behring Ag |
Treatment and prevention of remote ischemia-reperfusion injury
|
|
US9580511B2
(en)
|
2013-03-11 |
2017-02-28 |
Genzyme Corporation |
Site-specific antibody-drug conjugation through glycoengineering
|
|
JP6450364B2
(ja)
|
2013-03-13 |
2019-01-09 |
セセン バイオ, インコーポレイテッド |
眼送達のためのキメラサイトカイン製剤
|
|
CA2906566C
(en)
|
2013-03-14 |
2024-09-10 |
Macrogenics, Inc. |
Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor
|
|
US20140271641A1
(en)
|
2013-03-14 |
2014-09-18 |
University Of Guelph |
Thrombospondin-1 polypeptides and methods of using same
|
|
CN114717206A
(zh)
|
2013-03-15 |
2022-07-08 |
Atyr 医药公司 |
组氨酰-trna合成酶-fc缀合物
|
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
EP2970489A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Biotechnology Ltd |
Anti-cd25 antibodies and their uses
|
|
ES2699599T3
(es)
|
2013-03-15 |
2019-02-11 |
Abbvie Biotherapeutics Inc |
Variantes de Fc
|
|
WO2014151910A1
(en)
|
2013-03-15 |
2014-09-25 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
SG11201505926VA
(en)
|
2013-03-15 |
2015-09-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
|
MX2015013163A
(es)
|
2013-03-15 |
2016-04-04 |
Zyngenia Inc |
Complejos multiespecificos multivalente y monovalentes y sus usos.
|
|
US9260527B2
(en)
|
2013-03-15 |
2016-02-16 |
Sdix, Llc |
Anti-human CXCR4 antibodies and methods of making same
|
|
AU2014233478A1
(en)
|
2013-03-15 |
2015-09-24 |
Abbvie Biotechnology Ltd. |
Anti-CD25 antibodies and their uses
|
|
RS60538B1
(sr)
|
2013-03-15 |
2020-08-31 |
Glaxosmithkline Ip Dev Ltd |
Anti-lag-3 vezujući proteini
|
|
SG11201508170TA
(en)
|
2013-04-02 |
2015-11-27 |
Chugai Pharmaceutical Co Ltd |
Fc REGION VARIANT
|
|
US9963515B2
(en)
|
2013-04-29 |
2018-05-08 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
CA2909952C
(en)
|
2013-04-29 |
2021-10-12 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
|
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
|
EP3875106A1
(en)
|
2013-08-08 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
Purification of chimeric fviii molecules
|
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
|
TW201722994A
(zh)
|
2013-08-13 |
2017-07-01 |
賽諾菲公司 |
胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
|
|
BR112016002753A2
(pt)
|
2013-08-13 |
2017-11-21 |
Sanofi Sa |
anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
CA2922529A1
(en)
|
2013-08-28 |
2015-03-05 |
Stemcentrx, Inc. |
Novel sez6 modulators and methods of use
|
|
JP2016531915A
(ja)
|
2013-08-28 |
2016-10-13 |
ステムセントリックス, インコーポレイテッド |
部位特異的抗体コンジュゲーション方法および組成物
|
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
US10611794B2
(en)
|
2013-09-25 |
2020-04-07 |
Bioverativ Therapeutics Inc. |
On-column viral inactivation methods
|
|
WO2015048272A1
(en)
|
2013-09-25 |
2015-04-02 |
Amgen Inc. |
V-c-fc-v-c antibody
|
|
CA2925256C
(en)
|
2013-09-27 |
2023-08-15 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
|
SG11201602522VA
(en)
|
2013-10-02 |
2016-04-28 |
Medimmune Llc |
Neutralizing anti-influenza a antibodies and uses thereof
|
|
CR20160156A
(es)
|
2013-10-11 |
2016-11-01 |
Oxford Biotherapeutics Ltd |
Anticuerpos conjugados contra ly75 para el tratamiento del cáncer
|
|
SI3063275T1
(sl)
|
2013-10-31 |
2020-02-28 |
Resolve Therapeutics, Llc |
Terapevtske fuzije nukleaza-albumin in postopki
|
|
AU2014346792A1
(en)
|
2013-11-06 |
2016-06-02 |
Abbvie Stemcentrx Llc |
Novel anti-claudin antibodies and methods of use
|
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
|
EP4053560A1
(en)
*
|
2013-11-26 |
2022-09-07 |
The Brigham and Women's Hospital, Inc. |
Compositions and methods for modulating an immune response
|
|
EP3077546A4
(en)
|
2013-12-02 |
2017-04-26 |
Oncomed Pharmaceuticals, Inc. |
Identification of predictive biomarkers associated with wnt pathway inhibitors
|
|
TWI702316B
(zh)
|
2013-12-04 |
2020-08-21 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
|
KR20210125114A
(ko)
|
2013-12-09 |
2021-10-15 |
알라코스 인크. |
항-Siglec-8 항체 및 그의 사용 방법
|
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
CN106103476B
(zh)
|
2013-12-24 |
2020-11-27 |
阿尔金克斯有限公司 |
FcRn拮抗剂及使用方法
|
|
EA201691111A1
(ru)
|
2014-01-10 |
2017-01-30 |
Байоджен Ма Инк. |
Химерные белки фактора viii и их применение
|
|
JP2017506640A
(ja)
|
2014-02-14 |
2017-03-09 |
セントローズ, エルエルシー |
細胞外標的化薬物共役体
|
|
JP6825909B2
(ja)
|
2014-02-28 |
2021-02-03 |
アラコス インコーポレイテッド |
シグレック−8関連疾患を処置するための方法および組成物
|
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
SG11201607519VA
(en)
|
2014-03-14 |
2016-10-28 |
Genentech Inc |
Methods and compositions for secretion of heterologous polypeptides
|
|
US9738702B2
(en)
*
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
|
HUE061339T2
(hu)
|
2014-03-19 |
2023-06-28 |
Genzyme Corp |
Targetáló csoportok helyspecifikus glikotechnikai átalakítása
|
|
US9885086B2
(en)
|
2014-03-20 |
2018-02-06 |
Pharmacyclics Llc |
Phospholipase C gamma 2 and resistance associated mutations
|
|
CA2943242A1
(en)
|
2014-03-21 |
2015-09-24 |
X-Body, Inc. |
Bi-specific antigen-binding polypeptides
|
|
CA2944649C
(en)
|
2014-04-04 |
2022-06-21 |
Bionomics, Inc. |
Humanized antibodies that bind lgr5
|
|
AU2015244025B2
(en)
|
2014-04-08 |
2019-03-21 |
Boston Pharmaceuticals Inc. |
Binding molecules specific for IL-21 and uses thereof
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
JP6832709B2
(ja)
*
|
2014-05-16 |
2021-02-24 |
メディミューン,エルエルシー |
新生児Fc受容体結合が改変されて治療および診断特性が強化された分子
|
|
LT3148579T
(lt)
|
2014-05-28 |
2021-05-25 |
Agenus Inc. |
Anti-gitr antikūnai ir jų panaudojimo būdai
|
|
US20170211876A1
(en)
*
|
2014-06-12 |
2017-07-27 |
Hoffmann-La Roche Inc. |
Method for selecting antibodies with modified fcrn interaction
|
|
CN106573961B
(zh)
|
2014-06-20 |
2022-01-04 |
豪夫迈·罗氏有限公司 |
基于chagasin的支架组合物、方法和应用
|
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
WO2016011035A2
(en)
|
2014-07-15 |
2016-01-21 |
Medlmmune, Llc |
Neutralizing anti-influenza b antibodies and uses thereof
|
|
KR102524920B1
(ko)
|
2014-07-22 |
2023-04-25 |
아폴로믹스 인코포레이티드 |
항-pd-1 항체
|
|
SG10201901057UA
(en)
|
2014-08-05 |
2019-03-28 |
Cb Therapeutics Inc |
Anti-pd-l1 antibodies
|
|
EP3180024B1
(en)
|
2014-08-11 |
2022-05-18 |
University of Massachusetts |
Anti-ospa antibodies and methods of use
|
|
CA2959629C
(en)
|
2014-09-03 |
2023-10-31 |
Boehringer Ingelheim International Gmbh |
Compound targeting il-23a and tnf-alpha and uses thereof
|
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
|
EP3197916A2
(en)
|
2014-09-25 |
2017-08-02 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
CN107001440A
(zh)
|
2014-09-26 |
2017-08-01 |
拜耳制药股份公司 |
稳定化的肾上腺髓质素衍生物及其用途
|
|
WO2016054101A1
(en)
|
2014-09-29 |
2016-04-07 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
|
RU2021125449A
(ru)
|
2014-10-01 |
2021-09-16 |
Медиммьюн Лимитед |
Антитела к тикагрелору и способы применения
|
|
PL3204425T3
(pl)
|
2014-10-09 |
2021-03-08 |
Genzyme Corporation |
Glikomodyfikowane koniugaty przeciwciał z lekami
|
|
AU2015332533B2
(en)
|
2014-10-14 |
2018-08-30 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
|
|
AU2015336931B2
(en)
|
2014-10-23 |
2021-04-29 |
Kira Biotech Pty Limited |
CD83 binding proteins and uses thereof
|
|
PE20170908A1
(es)
|
2014-10-29 |
2017-07-12 |
Teva Pharmaceuticals Australia Pty Ltd |
VARIANTES DE INTERFERON a2b
|
|
US20160130324A1
(en)
*
|
2014-10-31 |
2016-05-12 |
Shire Human Genetic Therapies, Inc. |
C1 Inhibitor Fusion Proteins and Uses Thereof
|
|
CA2961439A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
|
WO2016073853A1
(en)
|
2014-11-06 |
2016-05-12 |
Scholar Rock, Inc. |
Anti-pro/latent-myostatin antibodies and uses thereof
|
|
RU2713131C1
(ru)
*
|
2014-11-06 |
2020-02-03 |
Ф. Хоффманн-Ля Рош Аг |
ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А
|
|
RS62003B2
(sr)
|
2014-11-10 |
2025-01-31 |
Medimmune Ltd |
Vezujući molekuli specifični za cd73 i njihove upotrebe
|
|
EP3789403A1
(en)
|
2014-11-11 |
2021-03-10 |
MedImmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
JP6805142B2
(ja)
|
2014-11-21 |
2020-12-23 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Cd73に対する抗体およびその使用
|
|
ES2826566T3
(es)
|
2014-11-21 |
2021-05-18 |
Bristol Myers Squibb Co |
Anticuerpos que comprenden regiones constantes pesadas modificadas
|
|
US9382321B2
(en)
|
2014-11-26 |
2016-07-05 |
Adventis Health System/Sunbelt, Inc. |
Effector-deficient anti-CD32A antibodies
|
|
SG11201703750XA
(en)
|
2014-12-10 |
2017-06-29 |
Genentech Inc |
Blood brain barrier receptor antibodies and methods of use
|
|
EP3233120A4
(en)
|
2014-12-19 |
2018-05-30 |
Monash University |
Il-21 antibodies
|
|
MX2017005774A
(es)
|
2014-12-19 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
|
|
EA201791366A1
(ru)
|
2014-12-19 |
2018-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к c5 и способы их применения
|
|
EP3789039A1
(en)
|
2014-12-22 |
2021-03-10 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
|
AR103268A1
(es)
|
2014-12-23 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra tigit
|
|
SG11201705721WA
(en)
|
2015-01-14 |
2017-08-30 |
Brigham & Womens Hospital Inc |
Treatment of cancer with anti-lap monoclonal antibodies
|
|
EP3250588A1
(en)
|
2015-01-29 |
2017-12-06 |
Board of Trustees of Michigan State University |
Cryptic polypeptides and uses thereof
|
|
CN114773469B
(zh)
|
2015-02-05 |
2025-12-19 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
|
|
WO2016131893A1
(en)
|
2015-02-18 |
2016-08-25 |
Medimmune Limited |
Incretin fusion polypeptides
|
|
TWI759261B
(zh)
|
2015-02-27 |
2022-04-01 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
|
MX386491B
(es)
|
2015-03-09 |
2025-03-18 |
argenx BV |
Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
|
|
MX387295B
(es)
|
2015-03-31 |
2025-03-18 |
Medimmune Ltd |
Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
|
|
FR3034420A1
(fr)
|
2015-03-31 |
2016-10-07 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-cd303
|
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
AU2016271111B2
(en)
|
2015-05-29 |
2022-04-28 |
Bristol-Myers Squibb Company |
Antibodies against OX40 and uses thereof
|
|
WO2016193497A1
(en)
|
2015-06-04 |
2016-12-08 |
Ospedale San Raffaele Srl |
Inhibitor of igfbp3/tmem219 axis and diabetes
|
|
CA2986080C
(en)
|
2015-06-04 |
2023-12-05 |
Ospedale San Raffaele Srl |
Inhibitor of igfbp3 for the treatment of intestinal disorders
|
|
NZ775762A
(en)
|
2015-06-05 |
2025-02-28 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
HK1254432A1
(zh)
|
2015-06-17 |
2019-07-19 |
Allakos Inc. |
用於治疗纤维性疾病的方法和组合物
|
|
CN108026172B
(zh)
|
2015-06-26 |
2022-04-29 |
赛诺菲生物技术公司 |
单克隆抗il-1racp抗体
|
|
MX2017016502A
(es)
|
2015-06-29 |
2018-03-12 |
Univ Rockefeller |
Anticuerpos contra cd40 con actividad agonista mejorada.
|
|
PE20180774A1
(es)
|
2015-07-23 |
2018-05-07 |
Boehringer Ingelheim Int |
Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos
|
|
PE20231958A1
(es)
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
AU2016302768B2
(en)
|
2015-07-31 |
2019-08-22 |
Medimmune Limited |
Methods for treating hepcidin-mediated disorders
|
|
UA126016C2
(uk)
|
2015-08-03 |
2022-08-03 |
Біовератів Терапеутікс Інк. |
Злитий білок фактора іх
|
|
JP6869987B2
(ja)
|
2015-09-01 |
2021-05-12 |
アジェナス インコーポレイテッド |
抗pd−1抗体及びその使用方法
|
|
RU2760582C2
(ru)
|
2015-09-02 |
2021-11-29 |
Иммутеп С.А.С. |
Анти-LAG-3 антитела
|
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
|
TWI799366B
(zh)
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
|
EA038146B1
(ru)
|
2015-09-15 |
2021-07-13 |
Сколар Рок, Инк. |
Антитела к про-/латентному миостатину и их применения
|
|
TWI703158B
(zh)
|
2015-09-18 |
2020-09-01 |
美商希佛隆公司 |
特異性結合tl1a之抗體
|
|
US11339213B2
(en)
|
2015-09-23 |
2022-05-24 |
Mereo Biopharma 5, Inc. |
Methods and compositions for treatment of cancer
|
|
SG10201913573UA
(en)
|
2015-10-01 |
2020-03-30 |
Heat Biologics Inc |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
|
UA128469C2
(uk)
|
2015-10-08 |
2024-07-24 |
Макродженікс, Інк. |
Спосіб лікування в7-н3-експресуючого раку
|
|
RU2694903C1
(ru)
|
2015-10-12 |
2019-07-18 |
АПРОДЖЕН КейАйСи ИНК. |
Антитела к CD43 и их применение для лечения рака
|
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
|
PL3374398T3
(pl)
|
2015-11-10 |
2020-08-24 |
Medimmune, Llc |
Cząsteczki wiążące swoiste dla ASCT2 i ich zastosowanie
|
|
AU2016361462B2
(en)
|
2015-11-27 |
2023-09-21 |
Csl Limited |
CD131 binding proteins and uses thereof
|
|
JP2019501124A
(ja)
|
2015-11-30 |
2019-01-17 |
アッヴィ・インコーポレイテッド |
抗huLRRC15抗体薬物コンジュゲート及びその使用方法
|
|
EP3383909B1
(en)
|
2015-11-30 |
2020-06-17 |
AbbVie Inc. |
Anti-human lrrc15 antibody drug conjugates and methods for their use
|
|
WO2017096179A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
CN108367069B
(zh)
|
2015-12-14 |
2022-08-23 |
宏观基因有限公司 |
对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
|
|
EA201891420A1
(ru)
|
2015-12-18 |
2019-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
|
|
EP3394098A4
(en)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
|
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
|
CN107406511B
(zh)
|
2015-12-31 |
2021-01-19 |
江苏恒瑞医药股份有限公司 |
Pcsk9抗体、其抗原结合片段及其医药用途
|
|
CN107531795B
(zh)
|
2016-01-05 |
2021-01-19 |
江苏恒瑞医药股份有限公司 |
Pcsk9抗体、其抗原结合片段及其医药用途
|
|
JP2019505512A
(ja)
|
2016-01-08 |
2019-02-28 |
バッシボディ アクスイェ セルスカプ |
治療用抗癌ネオエピトープワクチン
|
|
KR20180118659A
(ko)
|
2016-02-01 |
2018-10-31 |
바이오버라티브 테라퓨틱스 인크. |
최적화된 viii 인자 유전자
|
|
AR108034A1
(es)
|
2016-02-17 |
2018-07-11 |
Macrogenics Inc |
Moléculas de unión a ror1, y métodos de uso de las mismas
|
|
AU2017228470A1
(en)
|
2016-03-04 |
2018-08-30 |
Bristol-Myers Squibb Company |
Combination therapy with anti-CD73 antibodies
|
|
CN116063494A
(zh)
|
2016-03-04 |
2023-05-05 |
洛克菲勒大学 |
具有增强的激动剂活性的cd40的抗体
|
|
BR112018067747A2
(pt)
|
2016-03-04 |
2019-01-08 |
Shire Human Genetic Therapies |
proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne
|
|
EP3431102A4
(en)
|
2016-03-14 |
2019-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
|
|
US11066464B2
(en)
|
2016-03-21 |
2021-07-20 |
Kymab Limited |
Anti-malarial antibodies that bind circumsporozoite protein
|
|
US10745487B2
(en)
|
2016-03-22 |
2020-08-18 |
Bionomics Limited |
Method of treating cancer by administering an anti-LGR5 monoclonal antibody
|
|
SG11201808723UA
(en)
|
2016-04-04 |
2018-11-29 |
Shire Human Genetic Therapies |
Conjugated c1 esterase inhibitor and uses thereof
|
|
AU2017246794B2
(en)
|
2016-04-04 |
2024-07-04 |
Genzyme Corporation |
Anti-complement factor Bb antibodies and uses thereof
|
|
CN109069633A
(zh)
|
2016-04-15 |
2018-12-21 |
宏观基因有限公司 |
新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
|
|
EP3454864A4
(en)
|
2016-04-21 |
2021-01-13 |
Abbvie Stemcentrx LLC |
Novel anti-bmpr1b antibodies and methods of use
|
|
AU2017255077B2
(en)
|
2016-04-28 |
2024-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing preparation
|
|
IL321475A
(en)
|
2016-05-06 |
2025-08-01 |
Medimmune Llc |
Bispecific binding proteins and their uses
|
|
CA3024618A1
(en)
|
2016-05-27 |
2017-11-30 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis
|
|
KR102543118B1
(ko)
|
2016-05-27 |
2023-06-14 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
|
WO2017214452A1
(en)
|
2016-06-08 |
2017-12-14 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
|
TWI760396B
(zh)
|
2016-06-17 |
2022-04-11 |
日商中外製藥股份有限公司 |
抗肌抑素抗體及使用方法
|
|
RS63446B1
(sr)
|
2016-06-30 |
2022-08-31 |
Prothena Biosciences Ltd |
Kompozicije za lečenje amiloidoze
|
|
MA45554A
(fr)
|
2016-07-01 |
2019-05-08 |
Resolve Therapeutics Llc |
Fusions de binucléase optimisées.
|
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
|
WO2018007999A1
(en)
|
2016-07-08 |
2018-01-11 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
MA45674A
(fr)
|
2016-07-15 |
2019-05-22 |
Takeda Pharmaceuticals Co |
Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
|
|
JP7241677B2
(ja)
|
2016-07-19 |
2023-03-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗cd47併用療法
|
|
CA3032820A1
(en)
|
2016-08-02 |
2018-03-22 |
Visterra, Inc. |
Engineered polypeptides and uses thereof
|
|
BR112019002039A2
(pt)
|
2016-08-05 |
2019-05-07 |
Medimmune, Llc |
anticorpos anti-o2 e uso dos mesmos
|
|
CN116271014A
(zh)
|
2016-08-05 |
2023-06-23 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
US10538579B2
(en)
|
2016-08-15 |
2020-01-21 |
Board Of Regents, The University Of Texas System |
Bispecific pertussis antibodies
|
|
WO2018035107A2
(en)
*
|
2016-08-15 |
2018-02-22 |
Board Of Regents, The University Of Texas System |
Stabilized pertussis antibodies with extended half-life
|
|
CN110087680B
(zh)
|
2016-08-19 |
2024-03-19 |
百济神州有限公司 |
使用包含btk抑制剂的组合产品治疗癌症
|
|
JP2019534858A
(ja)
|
2016-09-09 |
2019-12-05 |
ジェネンテック, インコーポレイテッド |
Frizzledの選択的ペプチド阻害剤
|
|
EP3512883A1
(en)
|
2016-09-13 |
2019-07-24 |
Humanigen, Inc. |
Epha3 antibodies for the treatment of pulmonary fibrosis
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
|
KR20230133934A
(ko)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
IL326479A
(en)
|
2016-10-12 |
2026-04-01 |
Bioverativ Usa Inc |
Anti-c1s antibodies and methods of use thereof
|
|
CA3039686A1
(en)
|
2016-10-19 |
2018-04-26 |
Medimmune, Llc |
Anti-o1 antibodies and uses thereof
|
|
US11286295B2
(en)
|
2016-10-20 |
2022-03-29 |
Sanofi |
Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
|
|
WO2018075954A2
(en)
|
2016-10-21 |
2018-04-26 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
AU2017345786B2
(en)
|
2016-10-21 |
2024-08-01 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
US11312761B2
(en)
|
2016-10-21 |
2022-04-26 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
CA3041340A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
CA3044838A1
(en)
|
2016-12-02 |
2018-06-07 |
Bioverativ Therapeutics Inc. |
Methods of inducing immune tolerance to clotting factors
|
|
KR20190090827A
(ko)
|
2016-12-02 |
2019-08-02 |
바이오버라티브 테라퓨틱스 인크. |
키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
|
|
WO2018104893A1
(en)
|
2016-12-06 |
2018-06-14 |
Glaxosmithkline Intellectual Property Development Limited |
Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
|
|
IL307242B1
(en)
|
2016-12-07 |
2026-07-01 |
Agenus Inc |
Anti-CTLA-4 antibodies and methods of using them
|
|
CN110300599B
(zh)
|
2016-12-07 |
2024-07-02 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
EP3551220B1
(en)
|
2016-12-07 |
2025-01-29 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
EP3551655A2
(en)
|
2016-12-07 |
2019-10-16 |
Genentech, Inc. |
Anti-tau antibodies and methods of their use
|
|
HRP20250482T1
(hr)
|
2016-12-21 |
2025-06-20 |
Cephalon Llc |
Protutijela koja se specifično vežu na ljudski il-15 i njihove uporabe
|
|
BR112019012950A2
(pt)
|
2016-12-23 |
2019-11-26 |
Macrogenics, Inc. |
molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
|
|
MD3558391T2
(ro)
|
2016-12-23 |
2022-05-31 |
Immunogen Inc |
Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestora
|
|
TW201825515A
(zh)
|
2017-01-04 |
2018-07-16 |
美商伊繆諾金公司 |
Met抗體以及其免疫結合物及用途
|
|
AU2018205234B2
(en)
|
2017-01-06 |
2024-09-19 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
|
|
ES3055314T3
(en)
|
2017-01-06 |
2026-02-11 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
|
|
WO2018138170A1
(en)
|
2017-01-25 |
2018-08-02 |
Medimmune, Llc |
Relaxin fusion polypeptides and uses thereof
|
|
KR102590672B1
(ko)
|
2017-01-25 |
2023-10-18 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
JP7630906B2
(ja)
|
2017-02-01 |
2025-02-18 |
イェール・ユニヴァーシティー |
利尿薬耐性の治療
|
|
RS63818B1
(sr)
|
2017-02-17 |
2023-01-31 |
Denali Therapeutics Inc |
Konstruisani polipeptidi za vezivanje za receptor transferina
|
|
KR102654105B1
(ko)
|
2017-02-17 |
2024-04-04 |
사노피 |
디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
|
|
CN110997714B
(zh)
|
2017-02-17 |
2024-05-03 |
赛诺菲 |
对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子
|
|
WO2018151841A1
(en)
|
2017-02-17 |
2018-08-23 |
Sanofi |
Multispecific binding molecules having specificity to dystroglycan and laminin-2
|
|
BR112019017628A2
(pt)
|
2017-02-24 |
2020-07-07 |
Macrogenics, Inc. |
molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
|
|
JP7244428B2
(ja)
|
2017-02-27 |
2023-03-22 |
シャタック ラボ,インコーポレイテッド |
Vsig8ベースのキメラタンパク質
|
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
|
MA49886A
(fr)
|
2017-03-16 |
2020-06-24 |
Medimmune Ltd |
Anticorps anti-par2 et leurs utilisations
|
|
UY37651A
(es)
|
2017-03-31 |
2018-10-31 |
Swedish Orphan Biovitrum Ab Publ |
Polipéptido de unión al il-1r-i
|
|
JP7209298B2
(ja)
|
2017-03-31 |
2023-01-20 |
公立大学法人奈良県立医科大学 |
血液凝固第viii因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ix因子異常症の予防および/または治療に用いられる医薬組成物
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
BR112019017241A2
(pt)
|
2017-04-13 |
2020-04-14 |
Agenus Inc. |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
|
CA3058290A1
(en)
|
2017-04-18 |
2018-10-25 |
Universite Libre De Bruxelles |
Biomarkers and targets for proliferative diseases
|
|
ES2994451T3
(en)
|
2017-04-20 |
2025-01-24 |
Atyr Pharma Inc |
Compositions for treating lung inflammation
|
|
WO2018193427A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
EP3620531A4
(en)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
|
|
BR112019022912A2
(pt)
|
2017-05-05 |
2020-05-26 |
Allakos Inc. |
Métodos e composições para tratar doenças oculares alérgicas
|
|
EP3401332A1
(en)
|
2017-05-08 |
2018-11-14 |
MAB Discovery GmbH |
Anti-il-1r3 antibodies for use in inflammatory conditions
|
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
AU2018266893A1
(en)
|
2017-05-12 |
2019-12-05 |
Takeda Pharmaceutical Company Limited |
Recombinant follistatin-Fc fusion proteins and use in treating Duchenne muscular dystrophy
|
|
JOP20190271A1
(ar)
*
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
MX2019013132A
(es)
|
2017-05-25 |
2020-01-27 |
Bristol Myers Squibb Co |
Anticuerpos que comprenden regiones constantes pesadas modificadas.
|
|
GB201709970D0
(en)
|
2017-06-22 |
2017-08-09 |
Kymab Ltd |
Bispecific antigen-binding molecules
|
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
|
IL307197B2
(en)
*
|
2017-07-11 |
2026-03-01 |
Alexion Pharma Inc |
Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
|
|
ES2965486T3
(es)
|
2017-07-27 |
2024-04-15 |
Alexion Pharma Inc |
Formulaciones de anticuerpos anti-C5 de alta concentración
|
|
MX2020001593A
(es)
|
2017-08-09 |
2020-07-13 |
Bioverativ Therapeutics Inc |
Moleculas de acido nucleico y usos de las mismas.
|
|
AU2018318440A1
(en)
|
2017-08-15 |
2020-02-13 |
Kindred Biosciences, Inc. |
IgG Fc variants for veterinary use
|
|
CN111315767B
(zh)
|
2017-08-22 |
2025-03-18 |
萨纳生物有限责任公司 |
可溶性干扰素受体及其用途
|
|
SG11202000387YA
(en)
|
2017-08-25 |
2020-03-30 |
Five Prime Therapeutics Inc |
B7-h4 antibodies and methods of use thereof
|
|
KR102755742B1
(ko)
|
2017-09-11 |
2025-01-15 |
모나쉬 유니버시티 |
인간 트롬빈 수용체 par4 결합 단백질
|
|
US12134790B2
(en)
|
2017-09-27 |
2024-11-05 |
Inozyme Pharma, Inc. |
Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
|
|
JP7518764B2
(ja)
|
2017-10-26 |
2024-07-18 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量および投与
|
|
CN111315772A
(zh)
|
2017-10-31 |
2020-06-19 |
斯塔顿生物技术有限公司 |
抗apoc3抗体及其使用方法
|
|
KR20260090008A
(ko)
|
2017-11-01 |
2026-06-16 |
추가이 세이야쿠 가부시키가이샤 |
생물 활성이 저하된 항체 배리언트 및 아이소폼
|
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
末梢血からの末梢血リンパ球(pbl)の拡大培養
|
|
US20210179721A1
(en)
|
2017-11-29 |
2021-06-17 |
Csl Limited |
Method of treating or preventing ischemia-reperfusion injury
|
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
|
MA51032A
(fr)
|
2017-12-08 |
2021-03-17 |
Argenx Bvba |
Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
|
|
US11795226B2
(en)
|
2017-12-12 |
2023-10-24 |
Macrogenics, Inc. |
Bispecific CD16-binding molecules and their use in the treatment of disease
|
|
EP3724885A2
(en)
|
2017-12-15 |
2020-10-21 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
|
CN111788227B
(zh)
|
2017-12-27 |
2025-02-25 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
|
FR3076294B1
(fr)
|
2017-12-29 |
2022-01-28 |
Lab Francais Du Fractionnement |
Procede de purification d'anticorps a partir de lait brut
|
|
SG11202006157VA
(en)
|
2018-01-05 |
2020-07-29 |
Corvidia Therapeutics Inc |
Methods for treating il-6 mediated inflammation without immunosuppression
|
|
AU2019207600B2
(en)
|
2018-01-09 |
2025-01-09 |
Theriva Biologics, Inc. |
Alkaline phosphatase agents for treatment of neurodevelopmental disorders
|
|
MX2020007429A
(es)
|
2018-01-12 |
2020-10-15 |
Takeda Pharmaceuticals Co |
Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
|
|
US20210038744A1
(en)
|
2018-02-01 |
2021-02-11 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor viii
|
|
CN111699004A
(zh)
|
2018-02-06 |
2020-09-22 |
豪夫迈·罗氏有限公司 |
眼科疾病的治疗
|
|
CA3090795A1
(en)
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
EP3752195A4
(en)
|
2018-02-14 |
2021-11-17 |
Viela Bio, Inc. |
FELINE MCDONOUGH'S SARCOMA (FMS) -LIKE TYROSINKINASE-3 RECEPTOR LIGANDS (FLT3L) ANTIBODIES AND USES THEREOF IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
|
|
CN111787949A
(zh)
|
2018-02-15 |
2020-10-16 |
宏观基因有限公司 |
变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
|
|
WO2019165077A1
(en)
|
2018-02-21 |
2019-08-29 |
Five Prime Therapeutics, Inc. |
B7-h4 antibody formulations
|
|
KR20200144094A
(ko)
|
2018-03-02 |
2020-12-28 |
파이브 프라임 테라퓨틱스, 인크. |
B7-h4 항체 및 이의 사용 방법
|
|
TWI827585B
(zh)
|
2018-03-15 |
2024-01-01 |
日商中外製藥股份有限公司 |
對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
|
|
EP4275761A3
(en)
|
2018-03-20 |
2024-02-28 |
Theriva Biologics, Inc. |
Alkaline phosphatase agents for treatment of radiation disorders
|
|
EP3768302B1
(en)
|
2018-03-20 |
2025-05-07 |
Theriva Biologics, Inc. |
Intestinal alkaline phosphatase formulations
|
|
WO2019183266A1
(en)
*
|
2018-03-21 |
2019-09-26 |
ALX Oncology Inc. |
Antibodies against signal-regulatory protein alpha and methods of use
|
|
US12281160B2
(en)
|
2018-03-23 |
2025-04-22 |
Csl Limited |
Method of treating asthma
|
|
JP7390729B2
(ja)
|
2018-03-23 |
2023-12-04 |
ユニヴェルシテ リブル ドゥ ブリュッセル |
Wntシグナル伝達アゴニスト分子
|
|
CA3095086A1
(en)
|
2018-03-28 |
2019-10-03 |
Takeda Pharmaceutical Company Limited |
Subcutaneous dosing of anti-cd38 antibodies
|
|
PE20210313A1
(es)
|
2018-03-28 |
2021-02-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
|
|
WO2019195770A1
(en)
|
2018-04-06 |
2019-10-10 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-nrp2 antibodies
|
|
MX2020012251A
(es)
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
CN112118859A
(zh)
|
2018-05-16 |
2020-12-22 |
杰特有限公司 |
1型可溶性补体受体变体及其用途
|
|
KR102914074B1
(ko)
|
2018-05-18 |
2026-01-16 |
바이오버라티브 테라퓨틱스 인크. |
A형 혈우병의 치료 방법
|
|
EP3802593B1
(en)
|
2018-05-31 |
2024-09-11 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
|
|
CN112867394B9
(zh)
|
2018-06-04 |
2024-12-06 |
马萨诸塞州渤健公司 |
具有降低的效应功能的抗vla-4抗体
|
|
EP3802603A1
(en)
|
2018-06-04 |
2021-04-14 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
|
|
JP7486437B2
(ja)
|
2018-06-08 |
2024-05-17 |
アルジェニクス ビーブイ |
免疫性血小板減少症を治療する組成物及び方法
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
|
EP3806884B1
(en)
|
2018-06-15 |
2023-08-02 |
Amyl Therapeutics |
General amyloid interaction motif (gaim)
|
|
MX2020013466A
(es)
|
2018-06-26 |
2021-04-19 |
Immunogen Inc |
Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
|
|
JP7538723B2
(ja)
|
2018-06-28 |
2024-08-22 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
抗c5抗体の産生方法
|
|
KR20210027426A
(ko)
|
2018-07-03 |
2021-03-10 |
브리스톨-마이어스 스큅 컴퍼니 |
Fgf21 제제
|
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
|
LT4324851T
(lt)
|
2018-07-19 |
2025-10-10 |
|
Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAx抗-CD3抗體及其用途
|
|
AU2019312366B2
(en)
|
2018-07-26 |
2025-08-14 |
Atyr Pharma, Inc. |
Compositions and methods for treating NRP2-associated diseases
|
|
EP3830259A4
(en)
|
2018-08-02 |
2022-05-04 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
|
|
JP7602454B2
(ja)
|
2018-08-09 |
2024-12-18 |
バイオベラティブ セラピューティクス インコーポレイテッド |
核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
|
|
MX2021002292A
(es)
|
2018-08-29 |
2021-05-27 |
Shattuck Labs Inc |
Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.
|
|
CA3109139A1
(en)
|
2018-08-30 |
2020-03-05 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
CN112996805A
(zh)
|
2018-08-30 |
2021-06-18 |
Hcw生物科技公司 |
多链嵌合多肽和其用途
|
|
WO2020047333A1
(en)
*
|
2018-08-30 |
2020-03-05 |
HCW Biologics, Inc. |
Single-chain chimeric polypeptides and uses thereof
|
|
EP3844280A4
(en)
*
|
2018-08-31 |
2022-09-14 |
Yale University |
ENPP1 POLYPEPTIDES AND METHODS OF USE
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
|
EP3852617B1
(en)
|
2018-09-20 |
2025-09-10 |
SFJ Pharma X, Inc. |
Use of antibody fragments for reversing ticagrelor activity
|
|
CN113286812B
(zh)
|
2018-09-27 |
2025-05-30 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
EP3632929A1
(en)
|
2018-10-02 |
2020-04-08 |
Ospedale San Raffaele S.r.l. |
Antibodies and uses thereof
|
|
JP2022504287A
(ja)
|
2018-10-03 |
2022-01-13 |
スターテン・バイオテクノロジー・ベー・フェー |
ヒト及びカニクイザルapoc3に特異的な抗体、並びにその使用の方法
|
|
AU2019361923B2
(en)
|
2018-10-15 |
2026-07-09 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
TWI897855B
(zh)
|
2018-10-26 |
2025-09-21 |
美商免疫遺傳股份有限公司 |
E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
|
|
CN119033684A
(zh)
|
2018-10-29 |
2024-11-29 |
豪夫迈·罗氏有限公司 |
抗体制剂
|
|
US12240893B2
(en)
|
2018-10-30 |
2025-03-04 |
Alexion Pharmaceuticals, Inc. |
Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
|
|
BR112021008486A2
(pt)
|
2018-11-01 |
2021-10-26 |
Shandong New Time Pharmaceutical Co., Ltd |
Anticorpo biespecífico e seu uso
|
|
BR112021008549A2
(pt)
|
2018-11-05 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
|
|
EP3876989A4
(en)
|
2018-11-09 |
2022-12-07 |
University of Massachusetts |
Anti-cfae antibodies and methods of use
|
|
MX2021005708A
(es)
|
2018-11-16 |
2021-09-21 |
Bristol Myers Squibb Co |
Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
|
|
US12098195B2
(en)
|
2018-11-27 |
2024-09-24 |
Innovent Biologics (Suzhou) Co., Ltd. |
Anti-IL-23p19 antibody and use thereof in treating diseases
|
|
JP2022513653A
(ja)
|
2018-11-28 |
2022-02-09 |
ブリストル-マイヤーズ スクイブ カンパニー |
修飾された重鎖定常領域を含む抗体
|
|
WO2020116560A1
(ja)
|
2018-12-05 |
2020-06-11 |
株式会社バイカ・セラピュティクス |
抗体のFc領域改変体
|
|
US12428484B2
(en)
|
2018-12-06 |
2025-09-30 |
Alexion Pharmaceuticals, Inc. |
Anti-ALK2 antibodies and uses thereof
|
|
WO2020115281A1
(en)
|
2018-12-07 |
2020-06-11 |
Baxalta GmbH |
Proteinaceous molecules binding factor ixa and factor x
|
|
WO2020114616A1
(en)
|
2018-12-07 |
2020-06-11 |
Tillotts Pharma Ag |
Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
|
|
WO2020115283A1
(en)
|
2018-12-07 |
2020-06-11 |
Baxalta GmbH |
Bispecific antibodies binding factor ixa and factor x
|
|
TWI772724B
(zh)
|
2018-12-21 |
2022-08-01 |
英商克馬伯有限公司 |
具有共同輕鏈的FIXaxFX雙專一性抗體
|
|
BR112021012631A2
(pt)
|
2018-12-26 |
2021-12-14 |
Xilio Dev Inc |
Anticorpos anti-ctla4 e métodos de uso dos mesmos
|
|
US11447551B2
(en)
|
2018-12-28 |
2022-09-20 |
Sparx Bioscience Limited |
Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
|
|
CA3124352A1
(en)
|
2019-01-04 |
2020-07-09 |
Resolve Therapeutics, Llc |
Treatment of sjogren's disease with nuclease fusion proteins
|
|
CN113614107A
(zh)
|
2019-01-23 |
2021-11-05 |
Encefa公司 |
Cd31竞争剂及其用途
|
|
CN119735688A
(zh)
|
2019-02-26 |
2025-04-01 |
茵思博纳公司 |
高-亲和力抗-mertk抗体及其用途
|
|
MX2021010265A
(es)
|
2019-02-26 |
2021-09-23 |
Janssen Biotech Inc |
Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
|
|
SG11202109331QA
(en)
|
2019-03-01 |
2021-09-29 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
MA55209A
(fr)
|
2019-03-05 |
2022-01-12 |
Prothena Biosciences Ltd |
Procédés de traitement de l'amylose al
|
|
JP7601758B2
(ja)
|
2019-03-19 |
2024-12-17 |
中外製薬株式会社 |
Mta依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
|
|
JP7575401B2
(ja)
|
2019-04-03 |
2024-10-29 |
ジェンザイム・コーポレーション |
断片化が低減した抗アルファベータtcr結合ポリペプチド
|
|
GB2589049C
(en)
|
2019-04-11 |
2024-02-21 |
argenx BV |
Anti-IgE antibodies
|
|
EP4631523A3
(en)
|
2019-05-01 |
2025-12-31 |
Novo Nordisk A/S |
ANTI-IL-6 ANTIBODY FORMULATION
|
|
BR112021022666A2
(pt)
|
2019-05-14 |
2022-03-29 |
Werewolf Therapeutics Inc |
Frações de separação e seus métodos e uso
|
|
US11850248B2
(en)
|
2019-05-14 |
2023-12-26 |
Yuhan Corporation |
Therapies with 3rd generation EGFR tyrosine kinase inhibitors
|
|
MY208668A
(en)
|
2019-05-14 |
2025-05-23 |
Janssen Biotech Inc |
Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
|
|
EP3975999A4
(en)
|
2019-06-03 |
2023-07-19 |
Theriva Biologics, Inc. |
ALKALINE PHOSPHATASE FORMULATIONS AND THEIR USES
|
|
US20220227888A1
(en)
|
2019-06-07 |
2022-07-21 |
Amgen Inc. |
Bispecific binding constructs with selectively cleavable linkers
|
|
BR112021024632A2
(pt)
|
2019-06-07 |
2022-01-18 |
Argenx Bvba |
Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea
|
|
WO2020250033A1
(en)
|
2019-06-10 |
2020-12-17 |
Takeda Pharmaceutical Company Limited |
Combination therapies using cd-38 antibodies
|
|
CA3143584A1
(en)
|
2019-06-18 |
2020-12-24 |
Bayer Aktiengesellschaft |
Adrenomedullin-analogues for long-term stabilization and their use
|
|
AU2020294797B2
(en)
|
2019-06-21 |
2025-12-18 |
Immunitybio, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
CN114466663B
(zh)
|
2019-07-25 |
2026-01-02 |
建新公司 |
以FcRn拮抗剂治疗抗体介导的障碍的方法
|
|
WO2021021615A1
(en)
|
2019-07-26 |
2021-02-04 |
Shire Human Genetic Therapies, Inc. |
Recombinant heme oxygenase-1 (ho-1) for the treatment of sickle cell disease
|
|
MX2022001626A
(es)
|
2019-08-06 |
2022-03-02 |
Glaxosmithkline Ip Dev Ltd |
Composiciones biofarmaceuticas y procedimientos conexos.
|
|
CN114502583A
(zh)
|
2019-08-12 |
2022-05-13 |
杰特创新股份有限公司 |
补体c2结合蛋白及其用途
|
|
MX2022001882A
(es)
|
2019-08-12 |
2022-05-30 |
Aptevo Res & Development Llc |
Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
|
|
CN114787182A
(zh)
|
2019-08-13 |
2022-07-22 |
艾佩斯瑞生物制药公司 |
工程化的白细胞介素-2受体β激动剂
|
|
CN114585644A
(zh)
|
2019-08-30 |
2022-06-03 |
艾吉纳斯公司 |
抗cd96抗体及其使用方法
|
|
JP7803014B2
(ja)
|
2019-09-30 |
2026-01-21 |
バイオベラティブ セラピューティクス インコーポレイテッド |
レンチウイルスベクター製剤
|
|
AU2020358854B2
(en)
|
2019-10-03 |
2026-08-13 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-NRP2 antibodies
|
|
US20240148891A1
(en)
|
2019-10-18 |
2024-05-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CA3158174A1
(en)
|
2019-10-28 |
2021-05-06 |
Monash University |
Antibodies for binding plasmin
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
CN116478292A
(zh)
|
2019-11-15 |
2023-07-25 |
恩瑟拉有限责任公司 |
Tmem219抗体及其治疗性用途
|
|
EP4061839A1
(en)
|
2019-11-21 |
2022-09-28 |
Enthera S.R.L. |
Igfbp3 antibodies and therapeutic uses thereof
|
|
EP4065607A1
(en)
|
2019-11-29 |
2022-10-05 |
Kymab Limited |
Treatment for physiological iron overload
|
|
BR112022012010A2
(pt)
|
2019-12-18 |
2022-08-30 |
Hoffmann La Roche |
Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
|
|
PH12022551471A1
(en)
|
2019-12-20 |
2023-04-24 |
Momenta Pharmaceuticals Inc |
Antibodies against integrin alpha 11 beta 1
|
|
ES2992247T3
(es)
|
2020-01-08 |
2024-12-11 |
argenx BV |
Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
|
|
JP7858532B2
(ja)
|
2020-01-10 |
2026-05-14 |
ダイン セラピューティクス,インコーポレーテッド |
筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用
|
|
WO2021158938A1
(en)
|
2020-02-06 |
2021-08-12 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
WO2021163299A1
(en)
|
2020-02-11 |
2021-08-19 |
HCW Biologics, Inc. |
Chromatography resin and uses thereof
|
|
CA3169243A1
(en)
|
2020-02-11 |
2021-08-19 |
HCW Biologics, Inc. |
Methods of activating regulatory t cells
|
|
CN116670163A
(zh)
|
2020-02-11 |
2023-08-29 |
Hcw生物科技公司 |
治疗年龄相关疾病和炎性疾病的方法
|
|
BR112022015140A2
(pt)
|
2020-02-12 |
2022-10-11 |
Janssen Biotech Inc |
Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met
|
|
EP3868396A1
(en)
|
2020-02-20 |
2021-08-25 |
Enthera S.R.L. |
Inhibitors and uses thereof
|
|
JP7745556B2
(ja)
|
2020-02-21 |
2025-09-29 |
マクロジェニクス,インコーポレーテッド |
Cd137結合分子及びその使用
|
|
AU2021225962A1
(en)
|
2020-02-28 |
2022-10-20 |
Genzyme Corporation |
Modified binding polypeptides for optimized drug conjugation
|
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
|
WO2021195418A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
|
|
WO2021191836A1
(en)
|
2020-03-27 |
2021-09-30 |
Glaxosmithkline Biologicals Sa |
Hcvm pentamer binding antibodies
|
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
|
CA3173213A1
(en)
|
2020-03-31 |
2021-10-07 |
Roland B. WALTER |
Anti-cd33 antibodies and uses thereof
|
|
WO2021205027A1
(en)
|
2020-04-09 |
2021-10-14 |
Vaccibody As |
Individualized therapeutic anticancer vaccine
|
|
TWI900560B
(zh)
|
2020-04-20 |
2025-10-11 |
美商健臻公司 |
人類化抗補體因子bb抗體及其用途
|
|
CA3176425A1
(en)
|
2020-04-24 |
2021-10-28 |
Millennium Pharmaceuticals, Inc. |
Anti-cd19 antibodies and uses thereof
|
|
AU2021262794B2
(en)
|
2020-04-29 |
2026-06-18 |
Immunitybio, Inc. |
Anti-CD26 proteins and uses thereof
|
|
ES3075793T3
(en)
|
2020-05-13 |
2026-08-07 |
Disc Medicine Inc |
Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
|
|
AU2021273014A1
(en)
|
2020-05-13 |
2022-11-17 |
AbbVie Deutschland GmbH & Co. KG |
Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
PH12022553106A1
(en)
|
2020-05-17 |
2023-11-20 |
Astrazeneca Uk Liimited |
Sars-cov-2-antibodies and methods of selecting and using the same
|
|
US20210363512A1
(en)
|
2020-05-22 |
2021-11-25 |
Formycon Ag |
ACE2 fusion proteins and uses thereof
|
|
US12024545B2
(en)
|
2020-06-01 |
2024-07-02 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
CN115768475A
(zh)
|
2020-06-04 |
2023-03-07 |
Csl创新私人有限公司 |
治疗或预防急性呼吸窘迫综合征的方法
|
|
CA3184351A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Bispecific binding constructs
|
|
EP4162036A1
(en)
|
2020-06-09 |
2023-04-12 |
Inozyme Pharma, Inc. |
Soluble enpp1 or enpp3 proteins and uses thereof
|
|
EP4166574A4
(en)
|
2020-06-10 |
2025-01-15 |
Bica Therapeutics Inc. |
FUSION PROTEIN WITH ERYTHROPOIETIN POLYPEPTIDE
|
|
CR20230015A
(es)
|
2020-06-17 |
2023-02-17 |
Medimmune Ltd |
Fusiones heterodiméricas de relaxina y usos de las mismas
|
|
US20230242606A1
(en)
*
|
2020-06-21 |
2023-08-03 |
Technion Research & Development Foundation Limited |
Cxcl9 and variants thereof for immunotherapy of cancer diseases
|
|
EP4168047A4
(en)
*
|
2020-06-23 |
2024-08-21 |
Maddon Advisors LLC |
Anti-ccr5 monoclonal antibody-based compositions and methods
|
|
WO2021259227A1
(zh)
|
2020-06-23 |
2021-12-30 |
江苏康缘药业股份有限公司 |
抗cd38抗体及其用途
|
|
JP2023537565A
(ja)
|
2020-06-24 |
2023-09-04 |
バイオベラティブ セラピューティクス インコーポレイテッド |
タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第viii因子を除去する方法
|
|
CN116194478A
(zh)
|
2020-06-24 |
2023-05-30 |
阿雷克森制药公司 |
皮下(sc)施用抗c5抗体治疗补体相关病症
|
|
US20230355722A1
(en)
|
2020-06-29 |
2023-11-09 |
Resolve Therapeutics, Llc |
Treatment of sjogren’s syndrome with nuclease fusion proteins
|
|
US20240279353A1
(en)
|
2020-07-06 |
2024-08-22 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
AR122933A1
(es)
|
2020-07-10 |
2022-10-19 |
Novo Nordisk As |
Métodos para tratar la enfermedad cardiovascular
|
|
BR112023001942A2
(pt)
|
2020-08-06 |
2023-02-28 |
Bioverativ Usa Inc |
Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento
|
|
IL300257A
(en)
|
2020-08-10 |
2023-03-01 |
Astrazeneca Uk Ltd |
SARS-COV-2 antibodies for the treatment and prevention of COVID-19
|
|
AU2021328375A1
(en)
|
2020-08-18 |
2023-04-13 |
Cephalon Llc |
Anti-PAR-2 antibodies and methods of use thereof
|
|
JP7518286B2
(ja)
|
2020-08-25 |
2024-07-17 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hivを標的とする多重特異性抗原結合分子及び使用方法
|
|
KR20230060514A
(ko)
|
2020-09-01 |
2023-05-04 |
다케다 야쿠힌 고교 가부시키가이샤 |
인터루킨-2 뮤테인 및 이의 용도
|
|
CN116601173A
(zh)
|
2020-09-11 |
2023-08-15 |
阿雷克森制药公司 |
抗铜蓝蛋白抗体及其用途
|
|
CN116829592A
(zh)
|
2020-09-11 |
2023-09-29 |
免疫医疗有限公司 |
治疗性b7-h4结合分子
|
|
PH12023550779A1
(en)
|
2020-09-28 |
2023-11-20 |
Angitia Biomedicines Ltd |
Anti-sclerostin constructs and uses thereof
|
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
|
CA3195019A1
(en)
|
2020-10-06 |
2022-04-14 |
Maria Fardis |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
CA3195512A1
(en)
|
2020-10-14 |
2022-04-21 |
Vahe Bedian |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2022090469A2
(en)
|
2020-10-29 |
2022-05-05 |
Formycon Ag |
Ace2 fusion proteins and uses thereof
|
|
CA3202233A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic BioPharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
|
EP4251187A4
(en)
|
2020-11-25 |
2025-09-10 |
Xilio Dev Inc |
TUMOR-SPECIFIC CLASSIBLE LINKERS
|
|
AU2021390501A1
(en)
|
2020-12-01 |
2023-06-29 |
Aptevo Research And Development Llc |
Heterodimeric psma and cd3-binding bispecific antibodies
|
|
MX2023006573A
(es)
|
2020-12-03 |
2023-06-19 |
Amgen Inc |
Constructos de inmunoglobulina con multiples dominios de union.
|
|
EP4255933A4
(en)
*
|
2020-12-07 |
2025-07-23 |
Invetx Inc |
COMPOSITIONS FOR INCREASING THE HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USE
|
|
WO2022125566A1
(en)
*
|
2020-12-08 |
2022-06-16 |
Janux Therapeutics, Inc. |
Half-life extending compositions and methods
|
|
EP4259193A4
(en)
|
2020-12-09 |
2025-01-15 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
|
|
JP2024501452A
(ja)
|
2020-12-11 |
2024-01-12 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Braf阻害剤及び/またはmek阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療
|
|
US20240123067A1
(en)
|
2020-12-17 |
2024-04-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocyte therapies
|
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
|
WO2022127793A1
(zh)
|
2020-12-18 |
2022-06-23 |
珠海泰诺麦博生物技术有限公司 |
呼吸道合胞病毒特异性结合分子
|
|
JP2024501845A
(ja)
|
2020-12-31 |
2024-01-16 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス
|
|
AU2021414227A1
(en)
|
2020-12-31 |
2023-07-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的hla展示肽
|
|
JP2024504372A
(ja)
|
2021-01-22 |
2024-01-31 |
エルピス・バイオファーマシューティカルズ |
抗pd-l1モノクローナル抗体及びインターロイキン15(il-15)、インターロイキン15受容体15アルファまたはインターロイキン2との融合タンパク質
|
|
CA3206549A1
(en)
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
TW202317612A
(zh)
|
2021-03-01 |
2023-05-01 |
美商艾希利歐發展股份有限公司 |
用於治療癌症的ctla4及pd1/pdl1抗體之組合
|
|
WO2022187272A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
|
CA3205815A1
(en)
|
2021-03-03 |
2022-09-09 |
Alwin REITER |
Formulations of ace2 fc fusion proteins
|
|
JP2024509184A
(ja)
|
2021-03-05 |
2024-02-29 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍保存及び細胞培養組成物
|
|
TW202304480A
(zh)
|
2021-03-19 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球(til)中之與cd39/cd69選擇及基因剔除相關之til擴增之方法
|
|
CN118019546A
(zh)
|
2021-03-23 |
2024-05-10 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途
|
|
EP4314253A2
(en)
|
2021-03-25 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
|
WO2022207846A1
(en)
|
2021-03-31 |
2022-10-06 |
Cambridge Enterprise Limited |
Therapeutic inhibitors of gdf15 signalling
|
|
WO2022207785A1
(en)
|
2021-03-31 |
2022-10-06 |
Kymab Limited |
Antibodies to gfral
|
|
TW202304508A
(zh)
|
2021-03-31 |
2023-02-01 |
美商百歐維拉提夫美國公司 |
減少冷凝集素疾病患者之手術相關溶血
|
|
JP7829595B2
(ja)
|
2021-04-09 |
2026-03-13 |
武田薬品工業株式会社 |
補体因子dを標的とする抗体及びその使用
|
|
AU2022263418A1
(en)
|
2021-04-19 |
2023-10-26 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
PE20241789A1
(es)
|
2021-04-26 |
2024-09-06 |
Millennium Pharm Inc |
Anticuerpos anti-clec12a y usos de los mismos
|
|
AU2022266583A1
(en)
|
2021-04-26 |
2023-10-19 |
Millennium Pharmaceuticals, Inc. |
Anti-adgre2 antibodies and uses thereof
|
|
US20240269180A1
(en)
|
2021-05-17 |
2024-08-15 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US12252550B2
(en)
|
2021-05-20 |
2025-03-18 |
Dianthus Therapeutics Opco, Inc. |
Antibodies that bind to C1S and uses thereof
|
|
CA3220227A1
(en)
|
2021-05-28 |
2022-12-01 |
Matthew Bruce |
Combination therapies for treating cancer
|
|
EP4348260A2
(en)
|
2021-06-03 |
2024-04-10 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
|
CA3218481A1
(en)
|
2021-06-14 |
2022-12-22 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
|
JP2024523034A
(ja)
|
2021-06-18 |
2024-06-25 |
エフ. ホフマン-ラ ロシュ アーゲー |
二重特異性抗ccl2抗体
|
|
DK4358995T3
(da)
|
2021-06-23 |
2026-02-02 |
Scholar Rock Inc |
Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser
|
|
CA3226111A1
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
|
CA3226942A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
KR20240040786A
(ko)
|
2021-08-03 |
2024-03-28 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법
|
|
JP2024531151A
(ja)
|
2021-08-10 |
2024-08-29 |
ビリジアン セラピューティクス, インコーポレイテッド |
甲状腺眼疾患の処置のための組成物、用量および方法
|
|
IL310868A
(en)
*
|
2021-08-16 |
2024-04-01 |
Univ Yale |
Variants of interleukin-12 and methods of their use
|
|
WO2023021169A1
(en)
|
2021-08-20 |
2023-02-23 |
Intervet International B.V. |
Antibodies and igg fusion proteins with an extended half-life
|
|
JP2024534265A
(ja)
|
2021-08-23 |
2024-09-18 |
イミュニタス セラピューティクス,インコーポレーテッド |
抗cd161抗体及びその使用
|
|
IL311003A
(en)
|
2021-08-25 |
2024-04-01 |
Denali Therapeutics Inc |
Anti-2HER antibodies and methods of using them
|
|
JP2024532620A
(ja)
|
2021-08-30 |
2024-09-05 |
ラッセン・セラピューティクス1・インコーポレイテッド |
抗IL-11Rα抗体
|
|
WO2023032955A1
(ja)
|
2021-08-31 |
2023-03-09 |
大正製薬株式会社 |
抗成長ホルモン抗体
|
|
CA3231018A1
(en)
|
2021-09-09 |
2023-03-16 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1 talen knockdown
|
|
US20250000903A1
(en)
|
2021-09-24 |
2025-01-02 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
KR20240099190A
(ko)
|
2021-09-30 |
2024-06-28 |
씨젠 인크. |
암 치료를 위한 b7-h4 항체 약물 접합체
|
|
EP4412713A1
(en)
|
2021-10-05 |
2024-08-14 |
GlaxoSmithKline Intellectual Property Development Ltd |
Combination therapies for treating cancer
|
|
AU2022372894A1
(en)
|
2021-10-20 |
2024-04-18 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
|
US20230187042A1
(en)
|
2021-10-27 |
2023-06-15 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19之組成物
|
|
AU2022388729A1
(en)
|
2021-11-10 |
2024-05-16 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
EP4433160A1
(en)
|
2021-11-17 |
2024-09-25 |
Disc Medicine, Inc. |
Methods for treating anemia of kidney disease
|
|
EP4437112A1
(en)
|
2021-11-24 |
2024-10-02 |
Formycon AG |
Improved ace2 fusion proteins
|
|
WO2023094571A1
(en)
|
2021-11-25 |
2023-06-01 |
Formycon Ag |
Stabilization of ace2 fusion proteins
|
|
JP2024546877A
(ja)
|
2021-12-15 |
2024-12-26 |
メドイミューン・リミテッド |
ヘテロ二量体リラキシン融合物を使用した治療
|
|
IL313306A
(en)
|
2021-12-17 |
2024-08-01 |
Viiv Healthcare Co |
Combined treatments for HIV infections and their uses
|
|
IL314367A
(en)
|
2022-01-18 |
2024-09-01 |
argenx BV |
Antibodies to galectin 10
|
|
EP4469065A1
(en)
|
2022-01-28 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
JP2025503987A
(ja)
|
2022-01-28 |
2025-02-06 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
ペイロードを発現するように操作された腫瘍浸潤リンパ球
|
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Rq生物科技有限公司 |
抗體
|
|
AU2023228912A1
(en)
|
2022-03-03 |
2024-09-19 |
Yale University |
Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
|
|
KR20240159839A
(ko)
|
2022-03-09 |
2024-11-06 |
아스트라제네카 아베 |
FRα에 대한 결합 분자
|
|
EP4490517A1
(en)
|
2022-03-11 |
2025-01-15 |
Astrazeneca AB |
A scoring method for an anti-fr alpha antibody-drug conjugate therapy
|
|
JP2025512313A
(ja)
|
2022-04-06 |
2025-04-17 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球療法によるnsclc患者の治療
|
|
US12594323B2
(en)
|
2022-04-13 |
2026-04-07 |
Immunitybio, Inc. |
Methods of reducing neuroinflammation
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
CA3250968A1
(en)
|
2022-04-29 |
2023-11-02 |
23Andme, Inc. |
Antigen binding proteins
|
|
CR20240528A
(es)
|
2022-04-29 |
2025-04-04 |
Astrazeneca Uk Ltd |
Anticuerpos contra el sars-cov-2 y métodos para utilizarlos
|
|
AU2023264772A1
(en)
|
2022-05-02 |
2024-10-24 |
Novo Nordisk A/S |
Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
|
|
EP4522202A1
(en)
|
2022-05-10 |
2025-03-19 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
|
WO2023220597A1
(en)
|
2022-05-10 |
2023-11-16 |
Elpis Biopharmaceuticals |
Engineered interleukin-2 receptor beta reduced-binding agonist
|
|
KR20250037789A
(ko)
|
2022-06-15 |
2025-03-18 |
아르젠엑스 비브이 |
Fcrn/항원-결합 분자 및 사용 방법
|
|
IL317666A
(en)
|
2022-06-15 |
2025-02-01 |
Bioverativ Usa Inc |
Anti-complement formulation for C1S antibody
|
|
MA71249A
(fr)
|
2022-06-24 |
2025-04-30 |
Bioverativ Usa Inc. |
Méthodes de traitement de maladies médiées par complément
|
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
|
CN119630428A
(zh)
|
2022-07-12 |
2025-03-14 |
西托姆克斯治疗公司 |
Epcam免疫缀合物及其用途
|
|
US12110324B2
(en)
|
2022-07-22 |
2024-10-08 |
Flagship Pioneering Innovations Vi, Llc |
Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
|
|
AR130041A1
(es)
|
2022-07-27 |
2024-10-30 |
Cephalon Llc |
Formulaciones de anticuerpos anti-tl1a
|
|
CN119894931A
(zh)
|
2022-07-27 |
2025-04-25 |
赛福伦有限责任公司 |
用于治疗溃疡性结肠炎和克罗恩病的抗tl1a抗体
|
|
CN120659627A
(zh)
|
2022-07-29 |
2025-09-16 |
瑞泽恩制药公司 |
用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法
|
|
MA71631A
(fr)
|
2022-07-29 |
2025-05-30 |
Regeneron Pharmaceuticals, Inc. |
Particules virales reciblées vers le récepteur 1 de transferrine
|
|
IL318627A
(en)
|
2022-07-29 |
2025-03-01 |
Regeneron Pharma |
Anti-TFR charge fusions and methods of using them
|
|
EP4565683A1
(en)
|
2022-08-01 |
2025-06-11 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
JP2025528212A
(ja)
|
2022-08-18 |
2025-08-26 |
イムノコア リミテッド |
複数ドメイン結合性分子
|
|
TW202423994A
(zh)
|
2022-08-18 |
2024-06-16 |
英商英美偌科有限公司 |
多域結合分子
|
|
CN121293357A
(zh)
|
2022-08-22 |
2026-01-09 |
雅博得乐医疗公司 |
Dll3结合分子及其用途
|
|
CA3265178A1
(en)
|
2022-08-25 |
2024-02-29 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen-binding proteins and their uses
|
|
EP4580674A2
(en)
|
2022-08-30 |
2025-07-09 |
Flagship Pioneering Innovations VI, LLC |
Antigen binding molecules targeting programmed cell death protein 1 (pd-1)
|
|
US12054552B2
(en)
|
2022-09-21 |
2024-08-06 |
Sanofi Biotechnology |
Humanized anti-IL-1R3 antibody and methods of use
|
|
JP2026513101A
(ja)
|
2022-10-25 |
2026-04-23 |
アブリンクス エン.ヴェー. |
エフェクター機能が強化された糖鎖改変Fc変異ポリペプチド
|
|
EP4612277A1
(en)
|
2022-11-04 |
2025-09-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
|
AU2023371614A1
(en)
|
2022-11-04 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
US20260124242A1
(en)
|
2022-11-04 |
2026-05-07 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
JP2025537301A
(ja)
|
2022-11-13 |
2025-11-14 |
ジェネレイト バイオメディシンズ, インコーポレイテッド |
Sars-cov-2を標的とする抗原結合分子
|
|
CN120456916A
(zh)
|
2022-11-14 |
2025-08-08 |
瑞泽恩制药公司 |
抗fgfr3抗体和抗原结合片段及其使用方法
|
|
AU2023379457A1
(en)
|
2022-11-14 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
US20240190978A1
(en)
|
2022-11-15 |
2024-06-13 |
CSBioAsset LLC |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|
|
EP4619764A1
(en)
|
2022-11-18 |
2025-09-24 |
Universiteit Antwerpen |
Igfbp2 as biomarker for thoracic aortic aneurysm and dissections
|
|
TW202426490A
(zh)
|
2022-11-21 |
2024-07-01 |
美商黛安瑟斯醫療運營公司 |
結合c1s之抗體及其用途
|
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
WO2024112711A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Methods for assessing proliferation potency of gene-edited t cells
|
|
IL321288A
(en)
|
2022-12-09 |
2025-08-01 |
Astrazeneca Ab |
Dosing regimens using fusions of relaxin heterodimers
|
|
EP4386084A1
(en)
|
2022-12-14 |
2024-06-19 |
Formycon AG |
Improved ace2 fusion proteins
|
|
AR131398A1
(es)
|
2022-12-19 |
2025-03-12 |
Astrazeneca Ab |
Tratamiento de enfermedades autoinmunitarias
|
|
CN120677175A
(zh)
|
2022-12-22 |
2025-09-19 |
供石公司 |
肌生成抑制蛋白活化的选择性和强效抑制剂
|
|
EP4646433A1
(en)
|
2023-01-06 |
2025-11-12 |
Lassen Therapeutics, Inc. |
Anti-il-18bp antibodies
|
|
KR20250135226A
(ko)
|
2023-01-06 |
2025-09-12 |
다케다 야쿠힌 고교 가부시키가이샤 |
자가면역 질환의 치료를 위한 항-cd38 항체
|
|
WO2024148240A1
(en)
|
2023-01-06 |
2024-07-11 |
Lassen Therapeutics 1, Inc. |
ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE
|
|
TW202430560A
(zh)
|
2023-01-06 |
2024-08-01 |
美商拉森醫療公司 |
抗il-18bp抗體
|
|
WO2024151515A2
(en)
|
2023-01-09 |
2024-07-18 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
WO2024150074A2
(en)
|
2023-01-13 |
2024-07-18 |
Takeda Pharmaceutical Company Limited |
Coronavirus antibodies and therapeutic uses thereof
|
|
AU2024212070A1
(en)
|
2023-01-25 |
2025-07-31 |
Medimmune Limited |
Migraine therapy
|
|
TW202448517A
(zh)
|
2023-02-16 |
2024-12-16 |
瑞典商阿斯特捷利康公司 |
用治療性結合分子治療癌症的組合療法
|
|
AU2024229544A1
(en)
|
2023-03-02 |
2025-10-16 |
Alloy Therapeutics, Inc. |
Anti-cd22 antibodies and uses thereof
|
|
WO2024184206A1
(en)
|
2023-03-03 |
2024-09-12 |
Astrazeneca Ab |
Pharmaceutical formulation comprising heterodimeric relaxin fusion proteins and uses thereof
|
|
EP4676954A1
(en)
|
2023-03-07 |
2026-01-14 |
Scholar Rock, Inc. |
Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
|
|
EP4428158A1
(en)
|
2023-03-10 |
2024-09-11 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Lung cancer targeting human antibodies and therapeutic uses thereof
|
|
EP4428159A1
(en)
|
2023-03-10 |
2024-09-11 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Melanoma targeting human antibodies and therapeutic uses thereof
|
|
TW202444757A
(zh)
|
2023-03-14 |
2024-11-16 |
美商奧迪希治療公司 |
抗cd25抗原結合蛋白及其用途
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024194686A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
US20250002588A1
(en)
|
2023-04-07 |
2025-01-02 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
|
|
GB202306345D0
(en)
|
2023-04-28 |
2023-06-14 |
Immunocore Ltd |
Binding molecules
|
|
CN121038815A
(zh)
|
2023-04-29 |
2025-11-28 |
拜奥海芬治疗学有限公司 |
半乳糖缺陷型免疫球蛋白的双功能降解剂
|
|
AU2024273077A1
(en)
|
2023-05-17 |
2025-11-13 |
Odyssey Therapeutics, Inc. |
Modified single-domain antibodies
|
|
EP4720125A1
(en)
|
2023-05-30 |
2026-04-08 |
Paragon Therapeutics, Inc. |
Alpha4beta7 integrin antibody compositions and methods of use
|
|
GB202309512D0
(en)
|
2023-06-23 |
2023-08-09 |
Astrazeneca Ab |
Lilrb2 binding proteins and uses thereof
|
|
CN121729432A
(zh)
|
2023-06-23 |
2026-03-24 |
派克西斯肿瘤学公司 |
抗klrg1抗体及其用途
|
|
KR20260032566A
(ko)
|
2023-06-29 |
2026-03-09 |
오디세이 테라퓨틱스, 인코포레이티드 |
항-trailr2 항원-결합 단백질 및 그의 용도
|
|
EP4739706A1
(en)
|
2023-07-05 |
2026-05-13 |
CSL Innovation Pty Ltd |
Methods of treating or preventing a complication of sickle cell disease
|
|
CN122003247A
(zh)
|
2023-07-07 |
2026-05-08 |
维里迪安治疗公司 |
治疗活动性和慢性甲状腺眼病的方法
|
|
IL325907A
(en)
|
2023-07-13 |
2026-03-01 |
Iovance Biotherapeutics Inc |
Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
|
|
WO2025019790A1
(en)
|
2023-07-19 |
2025-01-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
|
|
WO2025022280A1
(en)
|
2023-07-21 |
2025-01-30 |
Astrazeneca Ab |
Treatment of neurodegenerative diseases
|
|
IL326018A
(en)
|
2023-07-28 |
2026-03-01 |
Regeneron Pharma |
Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease
|
|
AR133384A1
(es)
|
2023-07-28 |
2025-09-24 |
Regeneron Pharma |
Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida
|
|
IL326224A
(en)
|
2023-07-31 |
2026-03-01 |
Sixpeaks Bio Ag |
Antibody conjugates and fusion proteins
|
|
EP4762093A1
(en)
|
2023-08-14 |
2026-06-24 |
Paragon Therapeutics, Inc. |
Alpha 4 beta 7 integrin binding proteins and methods of use
|
|
EP4761754A2
(en)
|
2023-08-18 |
2026-06-24 |
Immatics Biotechnologies GmbH |
Peptides displayed by mhc for use in immunotherapy against different types of cancer
|
|
TW202525845A
(zh)
|
2023-08-23 |
2025-07-01 |
法商賽諾菲公司 |
基於ctla—4之溶體降解劑及其用途
|
|
WO2025046298A2
(en)
|
2023-09-01 |
2025-03-06 |
iTeos Belgium SA |
Anti-trem2 antibodies and methods of use
|
|
CN122122186A
(zh)
|
2023-09-06 |
2026-05-29 |
维里迪安治疗公司 |
抗igf-1r抗体的药物组合物
|
|
WO2025059487A2
(en)
|
2023-09-15 |
2025-03-20 |
Othair Prothena Limited |
Cell penetrating agents and uses thereof
|
|
WO2025059486A1
(en)
|
2023-09-15 |
2025-03-20 |
Prothena Biosciences Limited |
Anti-tdp-43 antibodies and uses thereof
|
|
CN122070299A
(zh)
|
2023-09-15 |
2026-05-19 |
普罗塞纳生物科学有限公司 |
细胞穿透剂及其用途
|
|
US20250109187A1
(en)
|
2023-09-28 |
2025-04-03 |
Novavax, Inc. |
ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
|
|
TW202517301A
(zh)
|
2023-10-06 |
2025-05-01 |
美商思進公司 |
用b7-h4抗體-藥物結合物治療晚期實體腫瘤之方法
|
|
EP4537907A1
(en)
|
2023-10-10 |
2025-04-16 |
Enthera S.r.l. |
Cd248 inhibitors and uses thereof
|
|
WO2025080751A2
(en)
|
2023-10-13 |
2025-04-17 |
Odyssey Therapeutics, Inc. |
Anti-cdh17 antigen-binding proteins and uses thereof
|
|
WO2025090910A2
(en)
|
2023-10-25 |
2025-05-01 |
Multiverse Pharma Inc. |
Antigen binding molecules targeting il-12 and il-23
|
|
WO2025094146A1
(en)
|
2023-11-02 |
2025-05-08 |
Immunogen Switzerland Gmbh |
Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
|
|
IL328125A
(en)
|
2023-11-06 |
2026-06-01 |
Iovance Biotherapeutics Inc |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
IL328264A
(en)
|
2023-11-14 |
2026-07-01 |
Janssen Pharmaceuticals Inc |
Anti-Respiratory Syncytial Virus Antibodies and Their Uses
|
|
KR20260115642A
(ko)
|
2023-11-20 |
2026-07-24 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
재조합 반응을 통해 이종다량체를 제조하는 방법
|
|
AU2024392535A1
(en)
|
2023-11-27 |
2026-06-04 |
Glaxosmithkline Intellectual Property Development Limited |
Il-33 binding antibodies
|
|
AU2024408268A1
(en)
|
2023-12-17 |
2026-07-09 |
Viridian Therapeutics, Inc. |
Compositions, doses, and methods for treatment of thyroid eye disease
|
|
AU2024403128A1
(en)
|
2023-12-19 |
2026-06-25 |
Vectory Therapeutics B.V. |
Anti-tdp-43 antibodies and uses thereof
|
|
GB202319605D0
(en)
|
2023-12-20 |
2024-01-31 |
argenx BV |
Monovalent binding molecules and methods of use
|
|
WO2025133694A1
(en)
|
2023-12-20 |
2025-06-26 |
argenx BV |
Fcrn/hsa-binding molecules and methods of use
|
|
CN122422356A
(zh)
|
2023-12-20 |
2026-07-17 |
豪夫迈·罗氏有限公司 |
与ceacam5结合的抗体
|
|
WO2025133290A1
(en)
|
2023-12-21 |
2025-06-26 |
Temper Bio |
Protein for immune regulation
|
|
WO2025147696A1
(en)
|
2024-01-05 |
2025-07-10 |
Resolve Therapeutics, Llc |
Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
|
|
WO2025151502A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Modified antibodies
|
|
WO2025151496A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025151492A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025151752A1
(en)
|
2024-01-10 |
2025-07-17 |
Xilio Development, Inc. |
Masked il-2 cytokines and methods of use thereof
|
|
WO2025149633A1
(en)
|
2024-01-12 |
2025-07-17 |
Laigo Bio B.V. |
Bispecific antigen binding proteins
|
|
AU2025213136A1
(en)
|
2024-01-24 |
2026-07-16 |
Shattuck Labs, Inc. |
Antibodies that bind tnfrsf25
|
|
WO2025158412A1
(en)
|
2024-01-26 |
2025-07-31 |
Biohaven Therapeutics Ltd. |
BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS
|
|
AU2025218720A1
(en)
|
2024-02-06 |
2026-05-21 |
Paragon Therapeutics, Inc. |
Il-23 antibody compositions and methods of use
|
|
WO2025171006A1
(en)
|
2024-02-06 |
2025-08-14 |
Paragon Therapeutics, Inc. |
Il-23 binding protein compositions and methods of use
|
|
WO2025171182A1
(en)
|
2024-02-08 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
|
|
WO2025181697A1
(en)
|
2024-02-26 |
2025-09-04 |
Biohaven Therapeutics Ltd. |
Bifunctional degraders of anti-pla2r antibody
|
|
US20250361297A1
(en)
|
2024-03-12 |
2025-11-27 |
Adaptam Therapeutics, S.L. |
Anti- siglec-15 binding molecules and methods of use
|
|
WO2025193746A1
(en)
|
2024-03-12 |
2025-09-18 |
Takeda Pharmaceutical Company Limited |
Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia
|
|
WO2025210538A1
(en)
|
2024-04-02 |
2025-10-09 |
Biohaven Therapeutics Ltd. |
Bifunctional degraders
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
EP4644413A1
(en)
|
2024-05-03 |
2025-11-05 |
Genmab B.V. |
Binding agents having altered fc-mediated effector functions
|
|
WO2025235919A1
(en)
|
2024-05-09 |
2025-11-13 |
Takeda Pharmaceutical Company Limited |
Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy
|
|
WO2025232879A1
(en)
|
2024-05-10 |
2025-11-13 |
Cytocares (Shanghai) Inc. |
Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
|
|
WO2025245160A1
(en)
|
2024-05-21 |
2025-11-27 |
Scholar Rock, Inc. |
Myostatin-selective inhibitors for treating metabolic disorders
|
|
WO2025255435A2
(en)
|
2024-06-07 |
2025-12-11 |
Odyssey Therapeutics, Inc. |
Antigen-binding proteins against serum albumin and uses thereof
|
|
WO2025255558A2
(en)
|
2024-06-07 |
2025-12-11 |
Odyssey Therapeutics, Inc. |
Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
|
|
WO2025260062A2
(en)
|
2024-06-13 |
2025-12-18 |
Flagship Pioneering Innovations Vi, Llc |
Antigen binding molecules targeting interleukin-4 receptor subunit alpha (il-4ra)
|
|
WO2025262216A1
(en)
|
2024-06-21 |
2025-12-26 |
Glaxosmithkline Intellectual Property Development Limited |
Multispecific antigen binding proteins binding to il23 and il18
|
|
WO2026006495A1
(en)
|
2024-06-25 |
2026-01-02 |
Alloy Therapeutics, Inc. |
Anti-wt1/hla-a2 antibody and uses thereof
|
|
WO2026006492A2
(en)
|
2024-06-25 |
2026-01-02 |
Ypsilon Therapeutics, Inc. |
Anti-prame/hla-a2 antibodies and uses thereof
|
|
WO2026006494A1
(en)
|
2024-06-25 |
2026-01-02 |
Alloy Therapeutics, Inc. |
Anti-cd3 antibodies and uses thereof
|
|
WO2026006809A1
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding tnfr2 and cd25 and uses thereof
|
|
WO2026006708A2
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Anti-cd25 antigen-binding proteins and uses thereof
|
|
WO2026006784A1
(en)
|
2024-06-28 |
2026-01-02 |
Iovance Biotherapeutics, Inc. |
Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
|
|
TW202617186A
(zh)
|
2024-06-28 |
2026-05-01 |
美商飛爾富來生物公司 |
Bcl-xl降解劑抗體結合物及其用途
|
|
TW202611088A
(zh)
|
2024-07-23 |
2026-03-16 |
美商雅博得樂醫療公司 |
5t4結合多肽及其用途
|
|
WO2026028159A1
(en)
|
2024-07-31 |
2026-02-05 |
Biohaven Therapeutics Ltd. |
Bifunctional degraders for the treatment of graves' disease
|
|
WO2026035866A1
(en)
|
2024-08-07 |
2026-02-12 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor
|
|
WO2026039779A1
(en)
|
2024-08-15 |
2026-02-19 |
Yale University |
Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding
|
|
WO2026044176A1
(en)
|
2024-08-23 |
2026-02-26 |
University Of Massachusetts |
Anti-etec adhesin protein antibodies and methods of use
|
|
WO2026052652A1
(en)
|
2024-09-03 |
2026-03-12 |
F. Hoffmann-La Roche Ag |
Cytokine receptor agonist
|
|
WO2026057740A1
(en)
|
2024-09-12 |
2026-03-19 |
Astrazeneca Ab |
Treatment of cancer with therapeutic binding molecules
|
|
WO2026072794A2
(en)
|
2024-09-26 |
2026-04-02 |
Iovance Biotherapeutics, Inc. |
Expansion processes for til product enriched with neoantigen- reactive t cells (narts)
|
|
WO2026068859A1
(en)
|
2024-09-30 |
2026-04-02 |
Université Libre de Bruxelles |
Wnt signaling agonist molecules in the treatment of a bone-related disease or disorder
|
|
WO2026073840A1
(en)
|
2024-10-01 |
2026-04-09 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to cd3 and uses therefor
|
|
WO2026078231A1
(en)
|
2024-10-11 |
2026-04-16 |
T-Therapeutics Limited |
Soluble non-aggregating immune ligand
|
|
WO2026078620A1
(en)
|
2024-10-11 |
2026-04-16 |
Medimmune Llc |
Cd22 antibody and drug conjugates and uses thereof
|
|
EP4729541A1
(en)
|
2024-10-16 |
2026-04-22 |
Paolo Fiorina |
Anti- igfbp7 antibodies and uses thereof
|
|
US20260109746A1
(en)
|
2024-10-22 |
2026-04-23 |
Gilead Sciences, Inc. |
Cd4-targeted il-15 molecules and methods of use
|
|
WO2026114819A1
(en)
|
2024-11-26 |
2026-06-04 |
Glaxosmithkline Intellectual Property Development Limited |
Il-13 antigen binding proteins
|
|
US12673112B2
(en)
|
2024-12-09 |
2026-07-07 |
Takeda Pharmaceutical Company Limited |
CCR8 antibodies, antibody conjugates, and uses thereof
|
|
WO2026125321A1
(en)
|
2024-12-10 |
2026-06-18 |
Intervet International B.V. |
Caninized il31rα antibodies with an extended half life
|
|
WO2026125320A1
(en)
|
2024-12-10 |
2026-06-18 |
Intervet International B.V. |
Caninized il31rα antibodies with an extended half life
|
|
WO2026125322A1
(en)
|
2024-12-10 |
2026-06-18 |
Intervet International B.V. |
CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE
|
|
WO2026131910A1
(en)
|
2024-12-19 |
2026-06-25 |
F. Hoffmann-La Roche Ag |
Treatment of inflammatory lung disease by combined inhibition of il-33 and il-6 with bispecific antibodies
|
|
WO2026136620A1
(en)
|
2024-12-19 |
2026-06-25 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding trailr2 and cdh17 and uses thereof
|
|
WO2026132145A1
(en)
|
2024-12-20 |
2026-06-25 |
F. Hoffmann-La Roche Ag |
Antibodies binding to tn-muc-1
|
|
WO2026132383A2
(en)
|
2024-12-20 |
2026-06-25 |
F. Hoffmann-La Roche Ag |
ANTIBODIES BINDING TO Tn-MUC-1
|
|
WO2026147753A1
(en)
|
2024-12-30 |
2026-07-09 |
Scholar Rock, Inc. |
Therapies for muscular dystrophies
|
|
WO2026150085A1
(en)
|
2025-01-10 |
2026-07-16 |
argenx BV |
Igg-binding molecules and methods of use thereof
|
|
WO2026152042A1
(en)
|
2025-01-10 |
2026-07-16 |
Scholar Rock, Inc. |
A novel class of musk agonists and uses thereof
|
|
WO2026159103A1
(en)
|
2025-01-23 |
2026-07-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2026161794A1
(en)
|
2025-01-27 |
2026-07-30 |
Cytomx Therapeutics, Inc. |
Epcam immunoconjugates and therapeutic uses thereof
|
|
EP4785960A1
(en)
|
2025-01-31 |
2026-08-05 |
SixPeaks Bio AG |
Glp-1 antibody conjugates
|